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Chapter 1.  
Introduction 
 
 
 
Sponges (phylum Porifera) are one of the simplest and most primitive animals 
on earth. They appeared in the world at least 600 million years ago, 50–100 million 
years before the Cambrian explosion.
1,2
 They can be found in oceans all around the 
world and even in freshwaters. Today, more than 8500 species of sponges are 
identified.
3
 Although only a few species of sponges are movable and carnivorous, 
almost all sponges are benthos and filter-feeders.
4
 
Neither nerve system, musculature, nor organs are observed in sponges, but 
they have cells which have specialized functions (Figure 1-1).
4,5,6
 Sponges have many 
“mouths” (ostia) on the “epidermis” (pinacoderm), take waters in their bodies, and 
capture organic particles in water by cells with flagellates (choanocytes). Taken water 
is excreted from relatively larger “mouth” (oscula) and this flow of water is supported 
by flagellates of choanocytes. Adjacent to pinacoderm and choanocytes, there is a 
gelatinous and non-living layer, called mesohyl. In this layer, sponge cells called 
2 
 
archeocytes are wandering and these cells are multi-functional: storage and digestion 
of food materials; metamorphosis into other specific cells, sperms and eggs; formation 
of the sponge body by secreting spicules and spongin, a kind of collagen protein. 
 
Figure 1-1. (a) A schematic figure of a typical sponge (arrows indicate flow of water) 
and (b) an enlarged view of the internal structure of a typical sponge. 
From ecological aspects, sponges provide habitats and shelters for other 
animals.
5
 Moreover, there is a variety of cyanobacteria and other bacteria in the 
mesohyl layer (Figure 1-1b).
6,7
 Although the percentages somehow differ among 
literatures, the amount of symbiotic bacteria can be up to 35–50% of total biomass of 
osculum 
ostium 
choanocyte 
base 
mesohyl 
pinacoderm 
pinacocyte 
archaeocyte 
spicule 
symbiotic bacterium 
a 
b 
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sponges.
6,7
 These bacteria have been thought as a great source of bioactive 
compounds.
8
 From sponges’ view, these compounds may work as anti-predators9, 
anti-competitors
10
, or anti-harmful microorganisms.
11
 One of the reasons why these 
simple and immovable animals can flourish in water environment is thought to be that 
sponges have these diverse “chemical weapons” in their body.12 On the other hand, 
from humans’ view, these compounds can be new pharmacologically active 
compounds.
13
 Actually, a number of reports about search for bioactive compounds 
from sponges have been published.
14
 
The subject of this doctoral thesis is to search for new bioactive compounds 
from the sponge Theonella swinhoei. To show that this sponge is a promising source of 
beneficial bioactive compounds, two aspects of this sponge are described in this 
chapter: (1) diversity and structural complexity of secondary metabolites in this 
sponge; (2) progress of research about biosynthesis of metabolites and biology of 
symbiotic bacteria in the sponge. 
 
Metabolites of the marine sponge Theonella swinhoei 
The sponges of the genus Theonella are one of the greatest sources of 
bioactive secondary metabolites among sponges. Today, more than 300 compounds 
4 
 
isolated from “Theonella” sponge are registered in the database.15 
There are several “subspecies” of the sponge Theonella swinhoei. We can find 
two types of sponges, T. swinhoei with white interior (T. swinhoei W) and T. swinhoei 
with yellow interior (T. swinhoei Y), at Hachijo Island, Tokyo, Japan (Figure 1-2). 
These sponges are different not only by their colors and shapes, but also by their 
metabolic profiles (Figure 1-3).  
  
  
Figure 1-2. Two types of the sponge Theonella swinhoei; their underwater photos (a: 
white interior; b: yellow interior) at Hachijo Island, Tokyo, Japan and their cross 
sections (c: white interior; d: yellow interior). Photos were taken by Dr. Yuji Ise, 
Nagoya University.
a b 
c d 
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a (from T. swinhoei W) 
 
          
Misakinolide A (1)                              Theonellamide F (2) 
 
 
b (from T. swinhoei Y)  
  
                      Onnamide A (3) 
 
                     Aurantoside A (4) 
 
 
 
 
 
 
 
 
Figure 1-3. Bioactive secondary metabolites from the sponge Theonella swinhoei (white and yellow) 
Cyclotheonamide A (5) 
Polytheonamide B (6) 
6 
 
From the sponge T. swinhoei W, structurally complex and bioactive macrolides, 
such as misakinolide A (1), and peptides, such as theonellamide F (2), were identified. 
Misakinolide A (1) was first reported as an antitumor compound from 
Okinawan T. swinhoei W
16
, and its structure was determined as a 20-menbered 
macrolide (Figure 1-4). One year later from the report, the compound which showed 
identical 
1
H and 
13
C NMR spectra as those of 1 was found in T. swinhoei W collected at 
Hachijo Island.
17
 In this report, the structure of misakinolide A was revised as a 
40-membered macrolide, which is the dimerized structure of the originally proposed 
20-membered macrolide. Finally, the absolute configuration of 1 was established by 
comparison of spectroscopic data of 1 with those of swinholide A, which is closely 
related compound of 1.
18,19
 
 
Figure 1-4. Originally proposed structure of misakinolide A. 
 Theonellamide F (2) was found in T. swinhoei collected at Hachijo Island.
20
 
This peptide has bicyclic structure containing characteristic unusual amino acids and 
histidinoalanine bridge, and exhibited bioactivities including antifungal activity and 
7 
 
cytotoxicity against some cancer cell lines. The structure of 2 was determined by careful 
analysis of the hydrolysate and 2D NMR spectra. Molecular target of 2 is revealed as 
3-hydroxysterol, including ergosterol, in cell membranes and it is expected that 2 
would be used as a research tool for exploring the function of sterols in cell 
membranes.
21
 
 Similarly, the sponge T. swinhoei Y contains a variety of secondary metabolites, 
which include some nitrogenous metabolites, such as onnamide A (3) and aurantoside A 
(4), and peptides, such as cyclotheonamide A (5) and polytheonamide B (6). As shown 
in Figure 1-3, structural features of metabolites in T. swinhoei Y are clearly different 
from those in T. swinhoei W. 
Onnamide A (3) was isolated from Okinawan T. swinhoei and exhibited potent 
antivirus activity against herpes simplex virus type-1, vesicular stomatitis virus, and 
coronavirus A-59.
22
 Later, it was revealed that 3 had cytotoxicity against murine and 
human tumor cells.
23
 The toxicity was exhibited by inhibition of protein synthesis
23
 and 
activation of stress-activated protein kinases.
24
 In addition, 3 is the first compound 
which was revealed to be biosynthesized by symbiotic bacteria in the sponge (described 
in the next part of the introduction).
25 
 
8 
 
 Aurantoside A (4) and B were found in T. swinhoei collected at Hachijo 
Island.
26
 Compound 4 exhibits orange color because it contains a conjugated heptaene 
system. Yellow color of T. swinhoei Y is due to the presence of this compound. 
Compound 4 showed cytotoxicity against P388 and L1210 leukemia cells. 
 Cyclotheonamide A (5) and B were also found in T. swinhoei collected at 
Hachijo Island.
27
 Compound 5 contains two characteristic amino acids, -keto-- 
arginine (Kar) and ,-unsaturated--tyrosine (Figure 1-5). The absolute configuration 
of Kar residue in 5 was established by total synthesis.
28
 Compound 5 inhibits the 
activity of serine proteases such as thrombin and trypsin, because Kar residue 
covalently bonds to the active sites of the enzymes.
29 
 
 
Figure 1-5. The structures of (a) -keto--arginine and (b) ,-unsaturated--tyrosine. 
 Polytheonamide B (6) was isolated from T. swinhoei collected at Hachijo 
Island.
30
 The structure of 6 is a linear peptide constructed by 48 amino acids with 
N-terminus blocked by 5,5-dimethyl-2-oxoheptanoyl group and has D/L alternating 
a b 
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stereochemistry. In solution, compound 6 adopts a -helical structure and forms 
channels in cell membranes.
31
 This accounts for the potent cytotoxicity of 6 (IC50 values 
was 68 pg/mL against P388 leukemia cells). Polytheonamides had been thought to be 
biosynthesized by non-ribosomal peptide synthase (NRPS).
32
 However, it was revealed 
by metagenome analysis that the peptides are ribosomal.
33
 
 As described, the sponge T. swinhoei is one of the most important sources to 
provide bioactive secondary metabolites among marine invertebrates. Therefore, many 
studies about biosynthesis of these compounds and symbiotic bacteria in the sponge are 
conducted.  
 
Symbiotic bacteria in the marine sponge Theonella swinhoei 
 Some sponge metabolites have structural similarity with those of bacterial 
origin, so it had been hypothesized that these compounds were biosynthesized by the 
symbiotic bacteria and not by the sponges themselves.
34,35 
 
 In the sponge T. swinhoei, there is a large amount of cyanobacteria, and they 
had been thought to be the producer of bioactive compounds.
19c
 However, Bewley et al. 
reported suggestive results about symbiotic bacteria in the sponge T. swinhoei.
36
 They 
separated symbiotic bacteria in Palauan T. swinhoei W and analyzed their metabolites. 
10 
 
They revealed that bioactive secondary metabolites, such as swinholide A and 
theopalauamide
37
, an analogue of theonellamides, were not detected from the 
cyanobacteria fraction, but from the filamentous bacterial fraction. Four years later, 
Schmidt et al. reported the result of 16S rRNA analysis of the bacterium, and identified 
the bacterium as a novel species, named “Candidatus Entotheonella palauensis”.38 
 In 2002, Piel identified the biosynthetic gene cluster of the cytotoxic polyketide, 
pederin (Figure 1-6a), from uncultured symbiontic bacteria in the beetle Paederus 
fuscipes.
39
 Pederin is closely related to the metabolites, theopederin
40
 and onnamide A, 
in T. swinhoei Y (Figures 1-6b and 1-6c), and this research showed the first evidence 
that symbiotic bacteria produce bioactive secondary metabolites. Two years later, Piel et 
al. identified the biosynthetic gene cluster of onnamide A from the metagenome of T. 
swinhoei Y, as mentioned above.
25
 Metagenomics is an efficient method to explore the 
biosynthesis of metabolites produced by uncultured symbiotic bacteria, as evidenced by 
the demonstration that polytheonamides are ribosomal.
33 
11 
 
 
Figure 1-6. The structures of (a) pederin, (b) theopederin A, and (c) onnamide A. 
 In 2013, Piel’s group and Japanese research groups reported that the 
filamentous bacteria, Candidatus Entotheonella facter, is the sole producer of bioactive 
secondary metabolites in T. swinhoei Y (Figure 1-7).
41
 Based on single cell genomics 
and metagenomics, this research revealed that almost all secondary polyketides and 
peptides identified in T. swinhoei Y, except for aurantosides, are biosynthesized by this 
bacterium. 
a 
b 
c 
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Figure 1-7. Florescence micrograph of filamentous bacteria, Candidatus Entotheonella 
facter (cited from reference 42). 
With this great breakthrough, genus Ca. Entotheonella bacteria were observed 
in some sponges which contain bioactive secondary metabolites, and biosynthetic gene 
clusters of some metabolites were identified in the genome of Ca. Entotheonella sp., 
such as misakinolide A in T. swinhoei W
42
, and calyculin A
43
 and kasumigamide
44
 in the 
sponge Discodermia calyx.
45,46
 Recently, some biological aspects of Ca. Entotheonella 
bacteria in T. swinhoei Y were reported
47
, and this bacterial group is becoming a bright 
resource of bioactive natural products. 
The bottleneck of the pharmaceutical use of sponge metabolites is the 
limitation of the amount of biomass and metabolites, so it is challenging to provide 
these metabolites for clinical trial and long-term supplies. Chemical synthesis is one of 
the ways to resolve the problem, but synthesis of complex natural products is sometimes 
not economical. Another way is cultivating the chemical producer or transferring the 
13 
 
biosynthetic genes to a culturable host.
7
 From this view, as biosynthetic research about 
metabolites of T. swinhoei is advanced, it is expected that bioactive compounds from the 
sponge could be easily applied to drug candidates or biological research tools. Therefore, 
I searched for novel bioactive compounds from T. swinhoei Y. 
In this doctoral thesis, the studies about bioactive peptides found in the sponge 
T. swinhoei Y are described. The second chapter describes the structures and biological 
activities of the new class of cyclic peptides, nazumazoles A–C. The third chapter 
illustrates nazumazoles D–F, monomeric analogue of nazumazoles A–C. The fourth 
chapter reports a new analogue of theonellamides, theonellamide H, which is contained 
in only several colonies and is the first compound of the theonellamide family which 
was identified in T. swinhoei Y. 
 
 
The contents of chapters 2 and 3 have been published as follows. 
(I)  Fukuhara, K.; Takada, K.; Okada, S.; Matsunaga, S. Org. Lett. 2015, 17, 2646–2648. 
(II)  Fukuhara, K.; Takada, K.; Okada, S.; Matsunaga, S. J. Nat. Prod. 2016, 79, 1694–1697. 
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Chapter 2. 
Nazumazoles A–C, cyclic pentapeptides dimerized through a disulfide bond from 
the marine sponge Theonella swinhoei 
 
 
2.1. Introduction 
 
We have analyzed the extracts of marine invertebrates by LC-MS and found 
that the extract of T. swinhoei Y contained unidentified metabolites, among which was 
an extraordinarily broad peak in ODS-HPLC (Figure 2-1, Figure S2-1). We successfully 
purified the peak, which exhibited cytotoxicity against P388 murine leukemia cells. We 
describe the isolation, structure elucidation, and biological activity of the constituents of 
the peak, nazumazoles A, B, and C (2-1–2-3) in this chapter. 
15 
 
 
Figure 2-1. LC-MS charts of the crude fraction of T. swinhoei Y: a) UV-VIS 
chromatogram (integration of 210–400 nm) with assignments of some known 
compounds
22,26,48,49,50
 and b) MS chromatogram of a sum of the responses of the ions at 
m/z 1185, 1199, and 1213. 
  
16 
 
2.2. Result and Discussion 
 
The MeOH extract of the sponge was partitioned between H2O and Et2O, and 
the organic layer was further partitioned between 90% MeOH and n-hexane. The H2O 
and 90% MeOH fractions were combined and fractionated by ODS flash 
chromatography, gel permeation chromatography, gel permeation HPLC, and 
ODS-HPLC to afford nazumazoles A–C (2-1–2-3) as an inseparable mixture. 
 
The HRESIMS of the mixture of nazumazoles A–C showed the molecular 
formulas of nazumazoles A, B, and C to be C50H68N14O16S2, C51H70N14O16S2, and 
C52H72N14O16S2, respectively. Interestingly, 2-1–2-3 gave different molecular ion peaks 
17 
 
in the ESIMS when the solvent of the sample and the carrier liquid was altered from 
MeCN to MeOH or EtOH. For example, the protonated ion peaks of nazumazole C 
(2-3) were observed at m/z 1213, 1277, and 1305, respectively, when using MeCN, 
MeOH, and EtOH, indicating that two molecules of MeOH or EtOH were incorporated 
into the molecular ion, reminiscent of the FABMS data of cyclotheonamide A, in which 
alcohol adducts were formed at the -keto--amino acid residue.27 
1
H and 
13
C NMR data (Table 2-1) suggested the peptide nature of the 
molecules with several amide 
1
H signals and carbonyl 
13
C signals. Interpretation of the 
COSY, HSQC, and TOCSY spectra revealed the presence of Cys, 2,3-diaminopropionic 
acid (Dpr), and 4-methylproline (Mpr) residues (Figure 2-2a and 2-2b). The -amino 
group of the Dpr residue was formylated as indicated by the HMBC correlations 
between H-14 (H 4.76) and the formyl 
13
C signals (C 160.7), and between the formyl 
1
H (H 7.99) and C-14 (C 50.5) signals (Figure 2-3). There were 
1
H NMR spin systems 
attributable to leucine and norvaline residues, for which nitrogen substituted methine 
1
H 
signals were correlated to a 
13
C signal at C 197.3 (197.2), suggesting the presence of 
-ketoleucine (Kle) and -ketonorvaline (Knv) residues (Figure 2-2c and 2-2d).51 The 
presence of a disubstituted oxazole ring was deduced from the HMBC data, in which a 
singlet aromatic 
1
H signal (H 8.54) directly coupled to a 
13
C signal at C 142.4 by 213 
18 
 
Hz was correlated to 
13
C signals at C 134.5 and C 163.5.
50
 Further HMBC correlations 
from H-23 (H 5.01) and H-24 (H 1.54) signals to C-22 (C163.4) signal suggested that 
the oxazole ring was a part of an alanine derived oxazole (Aox, Figure 2-2e). At this 
moment, two amide carbonyl 
13
C (C 159.6 and C 163.5) signals were left unassigned, 
one of which was in the -keto--amino acid residue and the other attached to the Aox 
residue as inferred from a process of elimination. 
 
 
Figure 2-2. The structures of constituent amino acids in nazumazoles A–C (2-1–2-3): 
(a) 2,3-diaminopropionic acid (Dpr); (b) 4-methylproline (Mpr); (c) -ketoleucine 
(Kle); (d) -ketonorvaline (Knv); (e) alanine derived oxazole (Aox). 
  
a b 
c d 
e 
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Table 2-1. 
1
H and 
13
C NMR Data for the Mixture of Nazumazoles A (2-1)–C (2-3) in 
DMSO-d6. 
residue position C
a, type H
a (J in Hz)  residue position C
a, type H
a (J in Hz) 
Knv 1 163.5,b C 
 
 Mpr 7 172.4, C   
 
2 197.2, C 
 
 8 59.5, CH 4.44, m  
 
3 54.6, CH 4.82, m  9 37.1, CH2 2.42, m  
 
4 31.4, CH2 1.94, m     1.29, m  
   
1.56, m   10 33.2, CH 2.21, m  
 
5 19.1, CH2 1.48, m   11 53.9, CH2 3.90, m  
   
1.40, m     2.94, m  
 
6 13.3, CH3 0.90, m   12 15.8, CH3 0.99, d (6.4)  
 3-NH  8.59, d (6.0)  N-CHO-Dpr 13 167.0, C   
Kle 1 163.5, C 
 
  14 50.5, CH 4.76, m  
 
2 197.3, C 
 
  15 38.7, CH3 3.68, m  
 
3 53.3, CH 4.87, m     3.45, m  
 
4 38.0, CH2 1.76, m   14-NH  7.98, m  
   
1.46, m   15-NH  7.48, m  
 
5 24.8, CH 1.78, m   CHO 160.7, CH 7.99, s  
 
6 21.0, CH3 0.90, m  Aox 19 159.6, C  
 
5-Me 22.9, CH3 0.93, m   20 134.5, C  
 
3-NH 
 
8.56, m   21 142.4, CH 8.54, s 
    
  22 163.5,b C  
      23 43.7, CH 5.01, m 
      24 15.7, CH3 1.54, d (6.9) 
 23-NH   8.95, m 
a
Recorded at 150 MHz for 
13
C and 600 MHz for 
1
H at 40 °C.  
b
Chemical shifts of C-1 and C-22 overlaped each other. 
 
 
 
 
 
 
20 
 
The amino acid sequences of 2-1–2-3 were determined by HMBC and NOESY 
data (Figure 2-3). HMBC correlations 3-NH/C-7, H-11a/C-13, H-14/C-13, H-15b/C-16, 
H-18b/C-16, and H-17a,b/C-19 suggested the sequence of -Knv (Kle)- 
Mpr-N-CHO-Dpr-Cys-. The amide 
1
H signal of the Cys residue was correlated to a 
13
C 
signal at C 159.6 and the nitrogen substituted methine 
1
H signal of the Aox residue was 
correlated to a 
13
C signal at C 163.5 in the HMBC spectrum. Therefore, the Cys residue 
was shown to be connected to the Aox residue via a carbonyl carbon and the Aox 
residue was linked to the Knv/Kle residue.  
 
Figure 2-3. Key COSY, TOCSY, HMBC, and NOESY correlations in 2-1–2-3. 
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Because the sizes of the resulting pentapeptide fragments were about half of the 
molecular weights of nazumazoles A–C, we considered that these peptides were either 
cyclic decapeptides or cyclic pentapeptides dimerized through a disulfide bond. In order 
to clarify this issue, the mixture of 2-1–2-3 was reduced consecutively with NaBH4 and 
DTT, and subjected to alkylation with 4-vinylpyridine to afford a mixture of 2-4a and 
2-4b and that of 2-5a and 2-5b, for which HRESIMS suggested that they were reduced 
cyclic pentapeptides with an S-pyridylethyl group.
52
 In 2-4a and 2-4b, the -carbon of 
Knv residue was reduced to a secondary alcohol (rKnv residue), whereas in 2-5a and 
2-5b, the pertinent residue was replaced by the reduced Kle (rKle) residue. Even though 
the structures of 2-4a, 2-4b, 2-5a, and 2-5b were confirmed by the 2D NMR data, each 
pair of diastereomers was inseparable by HPLC. Therefore, 2-1–2-3 were cyclic 
pentapeptides dimerized through a disulfide bond. We then examined the mode of 
dimerization by analyzing the NaBH4 reduction products of the mixture of nazumazoles 
A–C, which gave three sharp HPLC peaks (Figure S2-2, 2-6–2-8). The ESIMS and 2D 
NMR data demonstrated that the smallest congener (peak A, Figure S2-2) contained two 
rKnv residues, the second congener contained (peak B, Figure S2-2) one each of rKnv 
and rKle residue, and the largest congener (peak C, Figure S2-2) contained two rKle 
residues.
53
 
22 
 
 
 The absolute configuration of the amino acid residues in 2-1–2-3 was 
determined by Marfey’s method.54 Ala, Cys, Dpr, and Mpr were liberated by standard 
acid hydrolysis. Knv and Kle residues were analyzed as Nva and Leu residues, 
respectively, by oxidation with H2O2. Two diastereomers of 4-methylproline were 
synthesized from trans-4-hydroxy-L-proline as described in the literature and used as 
standards.
55
 Marfey’s analysis with detection by ESIMS revealed the presence of L-Ala, 
D-Cys, L-Dpr, cis-4-methyl-L-proline, L-Leu, and L-Nva (Figure S2-30–S2-35). 
 The mixture of nazumazoles A–C (2-1–2-3) exhibited cytotoxicity against 
P388 murine leukemia cells with an IC50 value of 0.83 M.  The cytotoxicity was 
diminished when the ketone in 2-1–2-3 was reduced, whereas the cytotoxicity was lost 
by further reduction and alkylation of the thiol group (Table S2-7). 
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2.3. Experimental Section 
 
General Experimental Procedure. 
UV spectra were measured on a Shimadzu BioSpec-1600 spectrophotometer. 
Optical rotations were measured on a Jasco DIP-1000 polarimeter. NMR spectra were 
measured on a JEOL delta 600 NMR spectrometer and referenced to residual solvent 
DMSO-d6 (H 2.49 for 
1
H and C 39.5 for 
13
C). ESI mass spectra were recorded on a 
JEOL JMS-T100LC mass spectrometer. LC-MS experiments were performed on a 
Shimadzu LC-20AD solvent delivery pump with a Nacalai Tesque Cosmosil 
2.5C18-MS-II column ( 2.0 mm × 100 mm) and interfaced to Bruker amaZon SL mass 
spectrometer. The results of XTT assay were recorded by Molecular Devices SPECTRA 
max M2. 
 
Extraction and Isolation of Nazumazoles A–C (2-1–2-3). 
The marine sponge Theonella swinhoei (22 kg) was collected at Hachijo Island. 
The sponge was extracted with MeOH at ambient temperature. The extract was dried in 
vacuo and partitioned between H2O and Et2O. The organic layer was further partitioned 
between 90% MeOH and n-hexane. The H2O and 90% MeOH layers were combined 
and subjected to ODS column chromatography by elution with H2O, MeOH-H2O (1:1), 
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and CHCl3-MeOH (1:1). The CHCl3-MeOH (1:1) fraction was subjected to ODS 
column chromatography with n-PrOH-H2O (2:3 and 3:1) and CHCl3-MeOH (1:1). The 
n-PrOH-H2O (2:3) fraction was subjected to gel permeation chromatography (Sephadex 
LH-20) with CHCl3-MeOH (1:1) to afford 3 fractions. The fraction that eluted after 
polytheonamides
30
 in the Sephadex LH-20 chromatography was subjected to ODS 
column chromatography with MeCN-H2O (1:9, 1:3, 2:3), MeCN, and MeOH. The 
MeCN-H2O (1:3) fraction was subjected to gel permeation HPLC on TOSOH TSK gel 
-2500 ( 20 mm  300 mm) at a flow rate of 2.8 mL min1 with detection at 235 nm, 
eluted with MeOH-H2O (3:7) to afford 7 fractions. 
Each fraction was analyzed by LC-MS, and the fractions that contain 2-1–2-3 
were combined and purified by ODS-HPLC on Cosmosil 5C18-AR-II ( 10 mm × 250 
mm) at a flow rate of 4 mL min
-1
 with detection at 220 nm. Gradient elution was 
performed using solvent A (0.2% acetic acid in H2O/MeCN = 9:1) and solvent B (0.15% 
acetic acid in MeCN) with the following linear gradient program: at 0 min, 94% A; at 
10 min, 94% A; at 35 min, 66% A; at 45 min; 66% A. As a result, we obtained the 
mixture of compounds 2-1–2-3 (43.4 mg). 
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Nazumazoles A–C (2-1–2-3): yellow powder; []D = +22.4° (c 0.05, MeOH); UV 
(MeOH) max (log 216 (4.13); 
1
H NMR and 
13
C NMR (DMSO-d6) see Table 2-1; 
HRESIMS obsd m/z 1207.4293 (M + Na)
+
 (C50H68N14NaO16S2 requires m/z 1207. 4277) 
for 2-1, 1221.4464 (M + Na)
+
 (C51H70N14NaO16S2 requires m/z 1221. 4433) for 2-2, and 
1235.4560 (M + Na)
+
 (C52H72N14NaO16S2 requires m/z 1235. 4590) for 2-3. 
 
Reduction of the Mixture of 2-1–2-3 with DTT. 
0.2 M DTT in H2O (100 L) was added to the mixture of 2-1–2-3 (100 g) in 
MeOH (100 L) and kept at 37 °C for 2 hours under N2. The reaction mixture was dried 
with a stream of N2 and applied to a column of ODS ( 5 mm × 10 mm) and eluted with 
MeCN-H2O (1:19, 3:2). The fraction eluted with MeCN-H2O (3:2) was dried in vacuo 
and analyzed by LC-MS. 
 
Reduction and Alkylation of the Mixture of 2-1–2-3. 
NaBH4 (2 mg) was added to the mixture of 2-1–2-3 (20 mg) in MeOH (1 mL) 
and left for 10 min at ambient temperature. To the reaction mixture, 5% acetic acid in 
H2O (1 mL) was added. The solution was applied to a column of ODS ( 5 mm  10 
mm) and eluted with H2O and MeCN-H2O (3:2). The fraction eluted with MeCN-H2O  
(3:2) was dried in vacuo to give a mixture of the reduced peptides (16 mg). To the 
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mixture dissolved in MeOH (1 mL) was added 1 M dithiothreitol (DTT) in H2O (1 mL) 
and kept at 37 C for 2 hours under N2. 4-Vinylpyridine (100 L) was added to the 
reaction mixture and incubated at rt in the dark for 24 hours under N2. The reaction 
mixture was dried with a stream of N2 and partitioned between H2O and CHCl3. The 
H2O layer was then purified by ODS-HPLC on Cosmosil 5C18-AR-II ( 10 mm × 250 
mm) at a flow rate of 2.8 mL min
1
 with detection at 235 nm. Gradient elution was 
performed using solvent A (0.5% acetic acid in H2O/MeCN = 9:1) and solvent B (0.45% 
acetic acid in MeCN) with the following linear gradient combination: at 0 min, 100% A; 
at 10 min, 100 % A; at 55 min, 50 % A. As a result, we obtained alkylated peptides 2-4 
(4.2 mg) and 2-5 (1.9 mg). For the sake of clarity, the mixture of 2-4a and 2-4b and that 
of 2-5a and 2-5b were indicated as 2-4 and 2-5, respectively. 
 
2-4: yellow powder; []D = +57.6° (c 0.1, MeOH); 
1
H NMR and 
13
C NMR (DMSO-d6) 
see Table S2-1; HRESIMS obsd m/z 723.28813 (M + Na)
+
, C32H44N8NaO8S requires 
m/z 723.29005. 
2-5: yellow powder; []D = +81.2° (c 0.05, MeOH); 
1
H NMR and 
13
C NMR 
(DMSO-d6) see Table S2-2; HRESIMS obsd m/z 715.32535 (M + H)
+
, C33H47N8O8S 
requires m/z 715.32375 
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Purification of the NaBH4 Reduction Products of the Mixture of 2-1–2-3. 
The mixture of reduced peptide (6.6 mg) was separated by ODS-HPLC on 
Cosmosil 5C18-AR-II ( 10 mm × 250 mm) at a flow rate of 4 mL min
-1
 with detection 
at 235 nm. Gradient elution was performed using solvent A (0.5% acetic acid in 
H2O/MeCN = 9:1) and solvent B (0.45% acetic acid in MeCN) with the following linear 
gradient combination: at 0 min, 100% A; at 10 min, 100% A; at 20 min, 89% A; at 40 
min, 89% A; at 50 min, 78% A; at 60 min, 78% A. As a result, we obtained 2-6 (0.9 mg), 
2-7 (1.2 mg), and 2-8 (0.7 mg). Each of 2-6, 2-7, and 2-8 was an inseparable mixture of 
four compounds. 
 
2-6: pale yellow powder; 
1
H NMR (DMSO-d6) see Table S2-3; HRESIMS obsd m/z 
1211.45526 (M + Na)
+
, C50H72N14NaO16S2 requires m/z 1211.45898. 
2-7: pale yellow powder; 
1
H NMR (DMSO-d6) see Table S2-4 and S2-5; HRESIMS 
obsd m/z 1225. 47719 (M + Na)
+
, C51H74N14NaO16S2 requires m/z 1225.47463. 
2-8: pale yellow powder; 
1
H NMR (DMSO-d6) see Table S2-6; HRESIMS obsd m/z 
1239.48263 (M + Na)
+
, C52H76N14NaO16S2 requires m/z 1239.49028 
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Marfey’s Analysis of 2-1–2-3. 
To the mixture of 2-6–2-8 (100 g) in MeOH (1 mL) was added 0.1 M 
dithiothreitol (DTT) in H2O (1 mL) and kept at 37 C for 2 hours under N2. The product 
was dried, redissolved in 6 N HCl, and kept at 110 °C for 3 hours. The reaction mixture 
was dried by a stream of N2 and dissolved in H2O (100 L), to which were added 1% 
L-FDAA in acetone (100 L) and 1 M NaHCO3 in H2O (20 L) and kept at 55 °C for 
30 min. After addition of 2 N HCl (10 L), the reaction mixture was analyzed by 
LC-MS at a flow rate of 0.5 mL min
1
. Gradient elution was performed using solvent A 
(0.5% acetic acid in H2O) and solvent B (0.45% acetic acid in MeCN) with the 
following linear gradient combination: at 0 min, 90% A; at 2 min, 90% A; at 32 min, 
30% A. Retention times of amino acids (min): 6.6 (m/z 374, Cys), 9.7 (m/z 342, Ala),  
12.4 (m/z 382, Mpr), and 15.7 (m/z 609, Dpr). Reduced Knv and Kle were detected by 
this analysis: 11.0 and 12.1 (m/z 400, rKnv), 12.8 and 13.8 (m/z 414, rKle). 
 
Absolute Configuration of the Knv and Kle Residues in 2-1–2-3. 
The mixture of compounds 2-1–2-3 (50 g) was dissolved in 5% NaOH in 30% 
H2O2 (250 L) and kept at 65 °C for 45 min. The solution was dried with a stream of N2, 
and the product was subjected to acid hydrolysis, derivatization with L-FDAA, and 
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analysis by LC-MS as described above. Retention times for amino acids (min): 13.4 
(m/z 370, Nva), 15.4 (m/z 384, Leu). Standard amino acids of L-Nva, D-Nva, L-Leu, and 
DL-Leu were derivatized with L-FDAA and analyzed by LC-MS. Retention times (min) 
for standard amino acids were 13.4 (L-Nva), 14.9 (D-Nva), 15.4 (L-Leu), and 17.8 
(D-Leu), so the absolute configuration of Knv and Kle were determined as L (Figure 
S2-34 and S2-35). 
 
trans-4-Hydroxy-L-proline Ethyl Ester. 
To a solution of trans-4-hydroxy-L-proline (100 mg) in EtOH (10 mL) was 
added SOCl2 (1.0 g) at 0 °C and refluxed for 4 h. The reaction mixture was diluted with 
petroleum ether and the product was filtered to afford trans-4-hydroxy-L-proline ethyl 
ester (95 mg). This material was used without further purification. 
 
N-Cbz-trans-4-Hydroxy-L-proline Ethyl Ester. 
trans-4-Hydroxy-L-proline ethyl ester (95 mg) in MeOH (2 mL) was cooled to 
0 °C, to which was added triethylamine (TEA, 215 L) and carbobenzyloxy chloride 
(CbzCl, 65 L), and stirred at rt for 16 h. The mixture was dried in vacuo, and the 
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product was dissolved in ethyl acetate (3 mL) and washed with 5% citric acid in H2O (3 
mL, 3 times) and H2O (3 mL, twice). The organic layer was dried with MgSO4. The 
product was subjected to silica gel column chromatography with petroleum ether/ethyl 
acetate (19:1, 4:1, 1:1) to afford N-Cbz-trans-4-hydroxy-L-proline ethyl ester (110 mg) 
as colorless oil from the petroleum ether/ethyl acetate (1:1) fraction. 
 
N-Cbz-4-Keto-L-proline Ethyl Ester. 
CrO3 (0.6 g) was dissolved in the mixture of CH2Cl2 (5 mL) and pyridine (1 
mL). N-Cbz-trans-4-hydroxy-L-Pro ethyl ester (110 mg) in CH2Cl2 (2 mL) was added to 
the solution, and the mixture was stirred at rt for 16 h. The mixture was filtered on silica 
pad with petroleum ether/ethyl acetate (1:1) to afford N-Cbz-4-keto-L-proline ethyl ester 
(100 mg) which was used without further purification. 
 
N-Cbz-4-Exomethylene-L-proline Ethyl Ester. 
To a solution of N-Cbz-4-keto-L-proline ethyl ester (100 mg) in anhydrous 
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toluene (1 mL) was added dimethyltitanocene (1 mL) and kept at 90 °C for 3 h. After 
cooled to rt, petroleum ether (50 mL) was added to the mixture and stirred for 30 min. 
The mixture was filtered on Celite and the solvent was dried in vacuo. The product was 
subjected to silica gel column chromatography with petroleum ether/diethyl ether (49:1, 
19:1, 9:1) to afford N-Cbz-4-exomethylene-L-proline ethyl ester (24 mg) as colorless oil 
from the petroleum ether/diethyl ether (9:1) fraction. 
 
cis-4-Methyl-L-proline. 
To a solution of N-Cbz-4-exomethylene-L-proline ethyl ester (4.0 mg) in 
CH2Cl2 (1 mL) was added 10 % Pd/C (1.5 mg), and the mixture was stirred for 16 h 
under an atmosphere of H2. The product was filtered on Celite to afford 
cis-4-methyl-L-proline ethyl ester (2.0 mg) as colorless oil. 
cis-4-Methyl-L-proline ethyl ester (2.0 mg) was dissolved in 6N HCl (300 L) 
and kept at 70 °C for 6 h. After cooled to rt, the mixture was washed with ethyl acetate 
(300 L, twice). The aqueous layer was dried under a stream of N2 to afford 
cis-4-methyl-L-proline (1.4 mg) as white powder. 
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trans-4-Methyl-L-proline. 
To N-Cbz-4-exomethylene-L-proline ethyl ester (3.5 mg) in CHCl3 was added 
Crabtree’s catalyst, and the mixture was stirred for 5 d under an atmosphere of H2. The 
product was subjected to silica gel column chromatography with petroleum 
ether/diethyl ether (49:1, 24:1, 47:3) to afford N-Cbz-trans-4-methyl-L-proline ethyl 
ester (3.6 mg) as colorless oil from the petroleum ether/diethyl ether (47:3) fraction. 
N-Cbz-trans-4-Methyl-L-proline ethyl ester (3.6 mg) was subjected to deprotection and 
hydrolysis as described above to afford trans-4-methyl-L-proline (1.9 mg) as white 
powder. 
 
Absolute Configuration of Cys, Ala, Mpr, and Dpr Residues in 2-1–2-3. 
To a solution of cis-4-methyl-L-proline (0.7 mg) in H2O (100 L) was added 
1% L-FDAA in acetone (100 L) and 1 M NaHCO3 in H2O (20 L) and kept at 55 °C 
for 30 min. After addition of 2 N HCl (10 L), the reaction mixture was analyzed by 
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LC-MS. cis-4-Methyl-L-proline (0.7 mg) was derivatized with D-FDAA in the same 
manner. trans-4-Methyl-L-proline (0.9 mg, respectively) was derivatized similarity. 
Standard amino acids of L-Cys, D-Cys, L-Ala, D-Ala, L-Dpr, DL-Dpr, L-Nva, D-Nva, 
L-Leu, and DL-Leu were derivatized with L-FDAA and analyzed by LC-MS. Retention 
times (min) for standard amino acids were 5.2 (L-Cys), 6.7 (D-Cys), 9.8 (L-Ala), 11.8 
(D-Ala), 12.5 (cis-4-methyl-L-proline), 12.6 (trans-4-methyl-L-proline), 13.5 
(trans-4-methyl-D-proline), 13.6 (cis-4-methyl-D-proline), 15.8 (L-Dpr), and 16.6 
(D-Dpr). Thus, the absolute configurations of amino acids in 2-1–2-3 were determined  
as D-Cys (6.6), L-Ala (9.7), cis-4-methyl-L-proline (12.4), L-Dpr (15.7), L-Nva (13.4) 
and L-Leu (15.4) (Figure S2-30–S2-35). 
 
XTT Assay against P388 Cells. 
P388 murine leukemia cells were cultured in PRMI 1640 (Wako Chemical) 
medium, supplemented with 100 g/mL of kanamycin (Wako Chemical) and 10% fetal 
bovine serum (ThermoFisher Scientific), at 37 °C under a 5% CO2 atmosphere. To each 
well of the 96-well microplate containing 100 L of 2 × 104 cells/mL, 100 L of test 
solution dissolved in PRMI-1640 medium was added, and the plate were incubated for 3 
days. After the addition of 50 L of 3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]- 
bis(4-methoxy-6-nitro)benzenesulfonic acid hydrate (XTT) solution (1 mg/mL) 
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containing 4% of phenazine methosulfate (PMS) solution (0.153 mg/mL) to each well, 
the plates were further incubated for 4 h. The absorbance at 450 nm was measured with 
a microplate reader.
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2.4. Supporting Information 
 
Table S2-1. 
1
H and 
13
C NMR Data for 2-4a and 2-4b in DMSO-d6. 
    2-4aa      2-4ba 
residue position cb, type H
b (J in Hz) HMBC residue position C
b, type H
b (J in Hz) 
rKnv 1 172.4, C 
 
  
 
rKnv 1 171.9, C 
 
 2 73.3, CH 3.83, m 1, 3 
 
 2 72.6, CH 3.62, d (8.9) 
 
3 50.1, CH 4.12, m 
  
 
3 50.6, CH 
3.95, ddd (8.3, 8.3, 
7.6) 
 4 35.4, CH2 1.47, m 6 
 
 4 33.2, CH2 1.75, m 
 5 18.4, CH2 1.32, m 
     
1.20, m 
 
  
1.25, m 6 
 
 5 17.7, CH2 1.35, m 
 6 13.6, CH3 0.82, m 4, 5 
 
 
  
1.20, m 
 3-NH 
 
7.90, m 
  
 6 13.7, CH3 0.79, m 
Mpr 7 171.0, C 
   
 3-NH 
 
8.23, m 
 8 60.0, CH 4.42, t (8.9) 7, 9 
 
Mpr 7 170.6, C 
 
 
9 36.2, CH2 
2.23, dddd (7.6, 
6.2, 6.2, 5.5) 
  
 
8 60.2, CH 4.26, t (8.9) 
 
  
1.14, ddd (11.7, 
11.7, 11.0)    
 
9 36.2, CH2 
2.12, dddd (8.3, 
6.9, 6.2, 5.5) 
 
10 32.9, CH 2.03, m 
  
 
  
0.95, ddd (11.7, 
11.7, 10.3)  
 11 54.3, CH2 3.83, m 
  
 10 32.9, CH 2.03, m 
 
  
2.70, m 10, 12 
 
 11 54.2, CH2 3.77, m 
 12 15.5, CH3 0.70, d (5.5) 9, 10, 11 
 
 
  
2.73, m 
N-CHO-Dpr 13 168.3, C 
   
 12 15.3, CH3 0.84, m 
 14 48.5, CH 4.55, m 
  
N-CHO-Dpr 13 168.3, C 
 
 15 40.5, CH2 3.77, m 14, 16 
 
 14 48.9, CH 4.49, m 
 
  
2.96, m 13, 14 
 
 15 40.5, CH2 3.81, m 
 14-NH 
 
8.42, m 
  
 
  
2.96, m 
 15-NH 
 
8.54, m 16 
 
 14-NH 
 
8.40, m 
 CHO 160.3, CH 7.95, s 14 
 
 15-NH 
 
8.56, m 
Cys 16 169.8, C 
   
 CHO 160.3, CH 7.95, s 
 17 53.6, CH 4.67, m 18, 19 
 
Cys 16 170.0, C 
 
 18 34.4, CH2 2.98, m 16, 1' 
 
 17 52.8, CH 4.70, m 
 
  
2.82, m 16, 17, 1' 
 
 18 34.4, CH2 3.00, m 
 17-NH 
 
8.26, d (9.6) 17, 19 
 
 
  
2.88, m 
ethyl-pyridine 1' 31.4, CH2 
2.76, dd (8.3, 
7.6) 
18, 3' 
 
 
17-NH 
 
8.10, d (9.6) 
 2' 33.8, CH2 2.83, m 3', 4', 7' 
 
ethyl-pyridine 1' 31.5, CH2 2.76, dd (8.3, 7.6) 
 3' 149.0, C 
   
 2' 33.8, CH2 2.82, m 
 4', 7' 123.7, CH 7.22, d (3.6)  2', 5', 6'  
 
 3' 149.0, C 
 
 5', 6' 149.1, CH 8.42, d (3.6) 4', 7' 
 
 4', 7' 123.7, CH 7.22, d (3.6)  
Aox 19 160.0, C 
   
 5', 6' 149.1, CH 8.42, d (3.6) 
 20 135.0, C 
   
Aox 19 160.0, C 
 
 21 142.1, CH 8.57, s 20, 22 
 
 20 135.3, C 
 
 22 163.8, C 
   
 21 142.7, CH 8.53, s 
 
23 42.8, CH 
4.82, dddd (7.6, 
6.9, 6.2, 6.2)  
1, 24 
 
 
22 164.2, C 
 
 24 16.6, CH3 1.53, d (6.9) 22, 23 
 
 23 43.2, CH 4.70, m 
  23-NH 
  
7.91, m 1, 23, 24 
 
 24 16.2, CH3 1.53, d (6.9) 
  
 
  23-NH   8.55, m 
a
2-4a is major isomer and 2-4b is minor isomer of alkylated nazumazoles A–C, respectively. bRecorded at 600 MHz and 25 °C.  
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Table S2-2. 
1
H and 
13
C NMR Data for 2-5a and 2-5b in DMSO-d6. 
2-5aa   
 
2-5ba 
residue position C
b, type H
b (J in Hz) HMBC 
 
residue position C
b, type H
b (J in Hz) 
rKle 1 172.2, C 
   
rKlec 1 unassigned 
 
 2 73.7, CH 3.81, m 1, 4 
 
 2 72.7, CH 3.54, d (8.9) 
 3 48.7, CH 4.21, m 
  
 3 49.2, CH 3.93, m 
 4 42.6, CH2 1.57, m 
  
 4 41.1, CH2 1.60, m 
 
  
1.21, m 
  
 
  
1.18, m 
 5 23.5, CH 1.66, m 
  
 5 23.5, CH 1.74, m 
 6 24.0, CH3 0.84, m 4, 5, 5-Me 
 
 6 23.3, CH3 0.85, m 
 5-Me 21.7, CH3 0.84, m 4, 5, 6 
 
 5-Me 21.1, CH3 0.76, d (6.2) 
 3-NH 
 
7.91, m 
  
 3-NH 
 
8.19, m 
Mpr 7 171.0, C 
   
Mprc 7 unassigned 
 
 8 60.0, CH 4.43, t (8.9) 7 
 
 8 60.2, CH 4.21, m 
 
9 36.0, CH2 
2.21, dddd (7.6, 
6.9, 6.9, 5.5)     
 
9 36.0, CH2 2.05, m   
 
  
1.12, ddd (11.7, 
11.7, 11.0)   
 
  
0.87, m 
 10 32.9, CH 2.01, m 
  
 10 32.9, CH 2.02, m 
 11 54.6, CH2 3.84, m 
  
 11 54.2, CH2 3.75, t (7.6) 
 
  
2.68, ddd (11.0, 
10.3, 9.6)    
 
  
2.72, m  
 12 15.3, CH3 0.67, d (6.2) 9, 10, 11 
 
 12 15.1, CH3 0.82, m 
N-CHO-Dpr 13 169.5, C 
   
N-CHO-Dprc 13 unassigned 
 
 
14 48.3, CH 
4.51, dddd (6.9, 
6.9, 4.8, 4.1)   
 
14 48.7, CH 4.41, m 
 15 40.7, CH2 3.84, m 14, 16 
 
 15 40.7, CH2 3.90, m 
 
  
2.83, m 
  
 
  
2.78, m 
 14-NH 
 
8.48, d (7.6) 
  
 14-NH 
 
8.48, d (7.6) 
 15-NH 
 
8.58, m 16 
 
 15-NH 
 
8.64, m 
 CHO 160.6, CH 7.94, s 14 
 
 CHO 160.4, CH 7.93, s 
Cys 16 169.8, C 
   
Cys 16 169.5, C 
 
 17 53.6, CH 4.68, m 19 
 
 17 52.8, CH 4.71, m 
 18 34.6, CH2 2.94, m 16, 17, 1' 
 
 18 34.4, CH2 2.96, m 
 
  
2.83, m 16, 17 
 
 17-NH 
 
8.17, d (9.6) 
 17-NH 
 
8.31, d (9.6) 19 
 
ethyl-pyridine 1' 31.7, CH2 2.77, m 
ethyl-pyridine 1' 31.7, CH2 2.77, m 2', 3' 
 
 2' 33.8, CH2 2.81, t (6.6) 
 2' 33.8, CH2 2.81, t (6.6) 1', 4', 7' 
 
 3' 149.0, C 
 
 3' 149.0, C 
   
 4', 7' 123.7, CH 7.22, d (4.2) 
 4', 7' 123.7, CH 7.22, d (4.2) 2', 5', 6' 
 
 5', 6' 149.1, CH 8.42, d (4.2) 
 5', 6' 149.1, CH 8.42, d (4.2) 4', 7' 
 
Aox 19 160.2, C 
 
Aox 19 160.0, C 
   
 20 135.3, C 
 
 20 135.1, C 
   
 21 141.5, CH 8.50, s 
 21 141.9, CH 8.57, s 20, 22 
 
 22 164.1, C 
 
 22 163.6, C 
   
 23 43.4, CH 4.63, qui (6.9) 
 23 42.9, CH 4.81, qui (6.9) 1 
 
 24 16.1, CH3 1.54, m 
 24 16.4, CH3 1.53, m 22, 23 
 
  23-NH  8.63, m 
23-NH   8.63, m 1, 22, 23 
 a2-5a is major isomer and 2-5b is minor isomer of alkylated nazumazoles A–C, respectively. bRecorded at 600 MHz and 25 °C. 
c
No HMBC correlation to amide carbonyl carbon was observed. 
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Table S2-3. 
1
H NMR Data for the Mixture of the Reduction Products of Nazumazole A 
(2-6) in DMSO-d6. 
major signals  minor signals 
amino 
   
amino 
  
acid position H
a (J in Hz) 
 
acid position H
a (J in Hz) 
rKnv 1 
  
rKnv 1 
 
 
2 3.84, m 
  
2 3.64, d (6.9) 
 
3 4.13, m 
  
3 4.00, m 
 
4 1.50, m 
  
4 1.76, m 
 5 1.35, m    1.22, m 
  
1.26, m 
  
5 1.37, m 
 
6 0.85, m 
   
1.24, m 
 
3-NH 7.75, d (7.8) 
  
6 0.85, m 
Mpr 7 
   
3-NH 8.14, m 
 8 4.40, dd (8.7, 9.2) 
 
Mpr 7 
 
 9 2.21, m 
  
8 4.27, dd (8.2, 9.6) 
 
 
1.09, m 
  
9 2.14, m 
 10 2.03, m 
   
0.99, m 
 11 3.80, m 
  
10 2.05, m 
 
 
2.72, m 
  
11 3.77, m 
 12 0.75, d (6.0) 
   
2.75, m 
N-CHO-Dpr 13 
   
12 0.86, m 
 14 4.55, m 
 
N-CHO-Dpr 13 
 
 15 3.75, m 
  
14 4.52, m 
 
 
3.04, m 
  
15 3.74, m 
 14-NH 8.33, d (7.8) 
   
3.07, m 
 15-NH 8.45, m 
  
14-NH 8.31, m 
 CHO 7.95, s 
  
15-NH 8.42, m 
Cys 16 
   
CHO 7.95, s 
 17 4.76, m 
 
Cys 16 
 
 18 3.10, m 
  
17 4.79, m 
 
 
2.94, m 
  
18 3.12, m 
 17-NH 8.21, d (9.6) 
   
2.96, m 
Aox 19 
   
17-NH 8.06, d (9.6) 
 20 
  
Aox 19 
 
 21 8.47, s 
  
20 
 
 22 
   
21 8.46, s 
 23 4.81, m 
  
22 
 
 24 1.53, m 
  
23 4.74, m 
23-NH 7.92, d (7.3)   
24 1.51, m 
 
 
23-NH 8.45, m 
a
Recorded at 600 MHz and 40 °C. 
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Table S2-4. 
1
H NMR Data for the Minor Signals of the Mixture of the Reduction 
Products of Nazumazole B (2-7) in DMSO-d6. 
amino 
   
amino 
  
acid position H
a (J in Hz) 
 
acid position H
a (J in Hz) 
rKnv 1 
  
rKleb 1' 
 
 
2 3.85, m 
  
2' unassigned 
 
3 4.12, m 
  
3' 4.20, m 
 
4 1.50, m 
  
4' 1.54, m 
 
5 1.34, m 
   
1.27, m 
  
1.27, m 
  
5' 1.64, m 
 
6 0.84, m 
  
6' 0.83, m 
 
3-NH 7.93, m 
  
5'-Me 0.85, d (7.8) 
Mpr 7 
   
3'-NH 7.88, d (8.7) 
 
8 4.40, dd (8.7, 8.2) 
 
Mpr 7' 
 
 
9 2.21, m 
  
8' 4.40, dd (8.7, 8.2) 
  
1.10, m 
  
9' 2.21, m 
 
10 2.01, m 
   
1.10, m 
 
11 3.80, m 
  
10' 2.01, m 
  
2.70, m 
  
11' 3.80, m 
 
12 0.74, d (6.0) 
   
2.70, m 
N-CHO-Dpr 13 
   
12' 0.70, d (6.0) 
 
14 4.54, m 
 
N-CHO-Dpr 13' 
 
 
15 3.75, m 
  
14' 4.51, m 
  
3.02, m 
  
15' 3.81, m 
 
14-NH 8.33, m 
   
2.91, m 
 
15-NH 8.43, m 
  
14'-NH 8.38, m 
 
CHO 7.95, s 
  
15'-NH 8.46, m 
Cys 16 
   
CHO 7.95, s 
 
17 4.74, m 
 
Cys 16' 
 
 
18 3.09, m 
  
17' 4.78, m 
  
2.92, m 
  
18' 3.09, m 
 
17-NH 8.24, d (9.6) 
   
2.92, m 
Aox 19 
   
17'-NH 8.29, d (9.6) 
 
20 
  
Aox 19' 
 
 
21 8.47, s 
  
20' 
 
 
22 
   
21' 8.47, s 
 
23 4.80, m 
  
22' 
 
 
24 1.52, m 
  
23' 4.80, m 
23-NH 7.98, m 
  
24' 1.52, d (6.9) 
  
23'-NH 7.98, m 
a
Recorded at 600 MHz and 40 °C. 
b
Neither COSY or TOCSY correlation to H-2’were not observed. 
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Table S2-5. 
1
H NMR Data for the Minor Signals of the Mixture of the Reduction 
Products of Nazumazole B (2-7) in DMSO-d6. 
amino 
   
amino 
  
acid position H
a (J in Hz) 
 
acid position H
a (J in Hz) 
rKnv 1 
 
 rKle 1' 
 
 
2 3.67, m  
 
2' 3.59, m 
 
3 4.00, m  
 
3' 3.95, m 
 
4 1.76, m  
 
4' 1.62, m 
  1.22, m    1.19, m 
 
5 1.51, m  
 
5' 1.74, m 
  
1.37, m  
 
6' 0.84, m 
 
6 0.86, m  
 
5'-Me 0.78, d (6.4) 
 
3-NH 8.39, m  
 
3'-NH 8.29, d (8.7) 
Mpr 7 
 
 Mpr 7' 
 
 
8 4.29, dd (9.2, 8.7)  
 
8' 4.23, m 
 
9 2.16, m  
 
9' 2.09, m 
  
0.99, m  
  
0.95, m 
 
10 2.05, m  
 
10' 2.01, m 
 
11 3.79, m  
 
11' 3.75, m 
  
2.75, m  
  
2.71, m 
 
12 0.83, m  
 
12' 0.83, m 
N-CHO-Dpr 13 
 
 N-CHO-Dpr 13' 
 
 
14 4.43, m  
 
14' 4.43, m 
 
15 3.85, m  
 
15' 3.85, m 
  
2.86, m  
  
2.86, m 
 
14-NH 8.38, d (7.8)  
 
14'-NH 8.38, d (7.8) 
 
15-NH 8.53, m  
 
15'-NH 8.53, m 
 
CHO 7.95, s  
 
CHO 7.95, s 
Cys 16 
 
 Cys 16' 
 
 
17 4.78, m  
 
17' 4.79, m 
 
18 3.10, m  
 
18' 3.10, m 
  
2.94, m  
  
3.00, m 
 
17-NH 8.10, d (8.2)  
 
17'-NH 8.18, d (8.7) 
Aox 19 
 
 Aox 19' 
 
 
20 
 
 
 
20' 
 
 
21 8.46, s  
 
21' 8.46, s 
 
22 
 
 
 
22' 
 
 
23 4.75, m  
 
23' 4.66, m 
 
24 1.53, m  
 
24' 1.53, m 
23-NH 8.61, m  
 
23'-NH 8.64, m 
a
Recorded at 600 MHz and 40 °C. 
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Table S2-6. 
1
H NMR Data for the Mixture of the Reduction Products of Nazumazole C 
(2-8) in DMSO-d6. 
major signals 
 
minor signals 
amino 
   
amino 
  
acid position H
a (J in Hz) 
 
acid position H
a (J in Hz) 
rKle 1 
  
rKle 1 
 
 
2 3.83, m  
 
2 3.56, m 
 
3 4.19, m  
 
3 3.95, m 
 
4 1.55, m  
 
4 1.73, m 
  
1.27, m  
  
1.19, m 
 
5 1.65, m  
 
5 1.65, m 
 
6 0.86, m  
 
6 0.86, m 
 
5-Me 0.85, d (6.9)  
 
5-Me 0.78, d (5.5) 
 
3-NH 7.78, d (10.0)  
 
3-NH 8.13, m 
Mpr 7 
  
Mpr 7 
 
 
8 4.40, t (8.7) 
  
8 4.22, m 
 
9 2.20, m 
  
9 2.08, m 
  
1.08, m 
   
0.91, m 
 
10 2.00, m 
  
10 2.01, m 
 
11 3.79, m 
  
11 3.74, m 
  
2.68, m 
   
2.72, m 
 
12 0.71, d (6.0) 
  
12 0.85, m 
N-CHO-Dpr 13 
  
N-CHO-Dpr 13 
 
 
14 4.50, m 
  
14 4.43, m 
 
15 3.79, m 
  
15 3.81, m 
  
2.90, m 
   
2.86, m 
 
14-NH 8.38, d (6.0) 
  
14-NH 8.38, d (6.0) 
 
15-NH 8.44, m 
  
15-NH 8.51, m 
 
CHO 7.94, s 
  
CHO 7.94, s 
Cys 16 
  
Cys 16 
 
 
17 4.76, m 
  
17 4.78, m 
 
18 3.09, m 
  
18 3.12, m 
  
2.94, m 
   
3.00, m 
 
17-NH 8.27, d (9.6) 
  
17-NH 8.15, d (9.6) 
Aox 19 
  
Aox 19 
 
 
20 
   
20 
 
 
21 8.46, s 
  
21 8.46, s 
 
22 
   
22 
 
 
23 4.80, m 
  
23 4.66, m 
 
24 1.53, d (6.9) 
  
24 1.53, d (6.9) 
23-NH 7.93, m 
  
23-NH 8.55, m 
a
Recorded at 600 MHz and 40 °C. 
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Table S2-7. IC50 Values of Nazumazoles and Their Derivatives against P388 Cells. 
  IC50 (M) 
2-1–2-3 0.83 
2-6 28 
2-7 20 
2-8 17 
2-4a, 2-4b, 2-5a, and 2-5b >50 
 
 
 
Figure S2-1. Two-dimensional LC-MS charts of 2-1–2-3 (in rectangle) in (a) crude 
sample and (b) purified sample; x-axis is retention time and y-axis is m/z. 
 
 
  
a 
b 
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Figure S2-2. LC-MS chart of the mixture of 2-6–2-8. 
 
 
Figure S2-3. UV-VIS spectrum of the mixture of 2-1–2-3 (MeOH, 210–400 nm).
43 
 
 
Figure S2-4. 
1
H NMR spectrum of the mixture of 2-1–2-3 in DMSO-d6 (600 MHz). 
 
Figure S2-5. 
13
C NMR spectrum of the mixture of 2-1–2-3 in DMSO-d6 (150 MHz). 
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Figure S2-6. COSY spectrum of the mixture of 2-1–2-3 in DMSO-d6 (600 MHz). 
 
Figure S2-7. HSQC spectrum of the mixture of 2-1–2-3 in DMSO-d6 (600 MHz). 
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Figure S2-8. TOCSY spectrum of the mixture of 2-1–2-3 in DMSO-d6 (600 MHz). 
 
Figure S2-9. HMBC spectrum of the mixture of 2-1–2-3 in DMSO-d6 (600 MHz). 
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Figure S2-10. NOESY spectrum of the mixture of 2-1–2-3 in DMSO-d6 (600 MHz). 
 
Figure S2-11. 
1
H NMR spectrum of the mixture of 2-4a and 2-4b in DMSO-d6 (600 MHz). 
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Figure S2-12. COSY spectrum of the mixture of 2-4a and 2-4b in DMSO-d6 (600 MHz). 
 
Figure S2-13. HSQC spectrum of the mixture of 2-4a and 2-4b in DMSO-d6 (600 MHz). 
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Figure S2-14. TOCSY spectrum of the mixture of 2-4a and 2-4b in DMSO-d6 (600 MHz). 
 
Figure S2-15. HMBC spectrum of the mixture of 2-4a and 2-4b in DMSO-d6 (600 MHz). 
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Figure S2-16. 
1
H NMR spectrum of the mixture of 2-5a and 2-5b in DMSO-d6 (600 MHz). 
 
Figure S2-17. COSY spectrum of the mixture of 2-5a and 2-5b in DMSO-d6 (600 MHz). 
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Figure S2-18. HSQC spectrum of the mixture of 2-5a and 2-5b in DMSO-d6 (600 MHz). 
 
Figure S2-19. TOCSY spectrum of the mixture of 2-5a and 2-5b in DMSO-d6 (600 MHz). 
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Figure S2-20. HMBC spectrum of the mixture of 2-5a and 2-5b in DMSO-d6 (600 MHz). 
 
Figure S2-21. 
1
H NMR spectrum of the mixture of the reduction products of nazumazole A (2-6) in DMSO-d6 (600 
MHz). 
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Figure S2-22. COSY spectrum of the mixture of the reduction products of nazumazole A (2-6) in DMSO-d6 (600 MHz). 
 
Figure S2-23. TOCSY spectrum of the mixture of the reduction products of nazumazole A (2-6) in DMSO-d6 (600 MHz). 
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Figure S2-24. 
1
H NMR spectrum of the mixture of the reduction products of nazumazole B (2-7) in DMSO-d6 (600 
MHz). 
 
Figure S2-25. COSY spectrum of the mixture of the reduction products of nazumazole B (2-7) in DMSO-d6 (600 MHz). 
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Figure S2-26. TOCSY spectrum of the mixture of the reduction products of nazumazole B (2-7) in DMSO-d6 (600 
MHz). 
 
Figure S2-27. 
1
H NMR spectrum of the mixture of the reduction products of nazumazole C (2-8) in DMSO-d6 (600 MHz). 
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Figure S2-28. COSY spectrum of the mixture of the reduction products of nazumazole C (2-8) in DMSO-d6 (600 MHz). 
 
Figure S2-29. TOCSY spectrum of the mixture of the reduction products of nazumazole C (2-8) in DMSO-d6 (600 MHz). 
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Figure S2-30. LC-MS charts of Marfey’s analyses of 2-1–2-3 (Cys). 
 
 
Figure S2-31. LC-MS charts of Marfey’s analyses of 2-1–2-3 (Ala). 
 
 
Figure S2-32. LC-MS charts of Marfey’s analyses of 2-1–2-3 (Mpr). 
57 
 
 
 
Figure S2-33. LC-MS charts of Marfey’s analyses of 2-1–2-3 (Dpr). 
 
 
Figure S2-34. LC-MS charts of Marfey’s analyses of 2-1–2-3 (Nva). 
 
 
Figure S2-35. LC-MS charts of Marfey’s analyses of 2-1–2-3 (Leu) 
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Figure S2-36. The graph of XTT assay of the mixture 2-1–2-3 against P388 murine 
leukemia cells; x-axis is concentration and y-axis is absorption at 450 nm. 
  
59 
 
Chapter 3. 
Nazumazoles D–F, cyclic pentapeptides that inhibit chymotrypsin, from the 
marine sponge Theonella swinhoei 
 
 
3.1. Introduction 
 
 In the previous chapter, the structures and bioactivities of dimeric cyclic 
pentapeptide, nazumazoles A–C (2-1–2-3) were described. These peptides were 
dimerized through disulfide bond, so it was assumed that there were reduced 
monomeric peptides in the sponge. The disulfide bond was necessary for cytotoxicity, 
and so, these monomeric peptides might have relatively low activity. To explore the 
presences and the bioactivities of these peptides, we searched for monomeric analogue 
of 2-1–2-3. As a result, we found another broad HPLC peak with the molecular 
weights of about 500 in the extract of T. swinhoei Y. We have purified the peak and 
further separated into three compounds. The isolation, structure elucidation, and 
biological activities of these compounds are the subject of this chapter. 
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3.2. Result and Discussion 
 
 The aqueous alcoholic extract of T. swinhoei Y was defatted and fractionated 
by ODS flash chromatography and gel permeation chromatography. We found that 
nazumazoles D–F (3-1–3-3) were barely separable by the HPLC on gel permeation 
column Shodex GS320. Each fraction was further purified by ODS-HPLC followed by 
another round of gel permeation HPLC to afford nazumazoles D (3-1, 1.8 mg), E (3-2, 
1.0 mg), and F (3-3, 0.7 mg) (Figure 3-1). 
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Figure 3-1. 2D LC-MS charts of nazumazoles. (a) the extract of T. swinhoei Y, (b) 
nazumazole D, (c) nazumazole E, and (d) nazumazole F; x-axis is retention time (min) 
and y-axis is m/z. Peaks of the contaminating lower homologues of nazumazole E were 
also observed in (c). 
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 The molecular formula of nazumazole D (3-1) was determined to be 
C26H37N7O8 by HRESIMS. In the 
1
H NMR spectrum of 3-1 (Table 3-1), there were 
five amide proton signals and five -proton signals of amino acid residues, which 
indicated the peptide nature of 1. Interpretation of the COSY, TOCSY, and HSQC 
spectra showed the presence of one each of 
1
H spin systems ascribable to norvaline 
(Nva), 4-methylproline (Mpr), 2,3-diaminopropionic acid (Dpr), -aminobutyric acid 
(Abu), and Ala. Acid hydrolysis afforded Mpr, Dpr, Abu, and Ala as revealed by 
Marfey’s method.54 In the HMBC spectrum, the -proton of the proposed Nva residue 
(H 4.83, H-3) was correlated to a shielded ketone carbonyl signal (C 197.6, C-2), 
which suggested that the keto-carbon was inserted between the -carbon and the 
carbonyl carbon of norvaline comprising the -ketonorvaline (Knv) residue (Figure 
3-2). To confirm this assignment, nazumazole D was reduced with NaBH4 followed by 
acid hydrolysis and derivatization with the Marfey’s reagent. The LC-MS analysis of 
the product afforded two peaks corresponding to the diastereomers of 
3-amino-2-hydroxyhexanoic acid (Figure S3-21). An amide carbonyl carbon signal 
was observed at C 163.8 (C-1) in the HMBC spectrum of 3-1, in accordance with the 
presence of the Knv residue. There was a heteroaromatic proton (H 8.60, H-21) and 
this proton was directly coupled to a carbon signal at C 142.2 (C-21) by 
1
JCH 214 Hz 
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and correlated to carbon signals at C 134.8 (C-20) and C 163.6 (C-22), indicating the 
presence of an oxazole ring.
50
 The carbon signal at C 163.6 (C-22) was also coupled to 
the - and -protons of an alanine-like spin system in the HMBC spectrum, 
demonstrating that the -methine was directly connected to the oxazole ring. The 
remaining unassigned carbon signal was atC 159.5, suggesting that this carbon was 
connected to C-4 of the oxazole ring to comprise the alanyloxazole (Aox) moiety as 
found in nazumazoles A–C. 
 
Figure 3-2. The structure of -ketonorvaline (Knv). 
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Table 3-1. 
1
H (600 MHz) and 
13
C NMR Data (150 MHz) of Nazumazole D (1) in 
DMSO-d6. 
amino acid position C,
a, b type H,
a (J in Hz) 
L-Knv 1 163.8, C 
 
 
2 197.6, C 
 
 
3 54.3, CH 4.83, m 
 
4 31.1, CH2 1.95, m 
   
1.54, m 
 
5 18.8, CH2 1.50, m 
   
1.38, m 
 
6 12.7, CH3 0.90, t (6.9) 
 
3-NH 
 
8.78, d (5.5) 
L-Mpr 7 172.7, C 
 
 
8 59.2, CH 4.45, dd (8.2, 9.2) 
 
9 36.7, CH2 2.42, m 
   
1.30, ddd (11.0, 11.5, 12.4) 
 
10 32.8, CH 2.20, m 
 
11 53.6, CH2 3.90, dd (6.9, 7.3) 
   
2.92, dd (9.6, 10.1) 
 
12 15.6, CH3 0.96, d (4.6) 
N--CHO--L-Dpr 13 166.9, C 
 
 
14 50.4, CH 4.74, m 
 
15 38.4, CH2 3.72, m 
   
3.39, m 
 
14-NH 
 
7.89, d (5.5) 
 
15-NH 
 
7.40, m 
 
CHO 160.5, CH 7.99, s 
D-Abu 16 172.4, C 
 
 
17 55.3, CH 4.20, m 
 
18 25.1, CH2 1.71, m 
   
1.50, m 
 
18-Me 10.0, CH3 0.81, t (6.9) 
 
17-NH 
 
7.70, d (9.2) 
L-Aox 19 159.5, C 
 
 
20 134.8, C 
 
 
21 142.2, CH 8.60, s 
 
22 163.6, C 
 
 
23 43.4, CH 5.03, q (7.3) 
 
24 15.2, CH3 1.54, d (5.5) 
23-NH 
 
9.09, d (7.8) 
a
Recorded at 25 °C. 
b13
C chemical shifts were obtained by HSQC and HMBC experiments. 
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 The amino acid sequence of 3-1 was determined by interpretation of the 
NOESY and HMBC data (Figure 3-3). NOESY cross-peaks were observed between 
the NH of the Abu residue (H 7.70, 17-NH) and the -NH of the Dpr residue (H 7.40, 
15-NH) demonstrating that the -amino group in the Dpr residue was connected to the 
carboxyl group of the Abu residue. There was a formyl group (H 7.99, CHO) and this 
proton signal gave NOESY cross-peaks with the -NH and -proton of the Dpr 
residue (H 7.89, NH-14; H 4.74, H-14), showing that the -amino group of the Dpr 
residue was formylated. NOESY correlations between the -protons of the Mpr residue 
(H 3.90, H-11a; H 2.92, H-11b) and the -proton of the Dpr residue (H 4.74, H-14) 
showed the connection between the Dpr residue and the Mpr residue, whereas the 
NOESY cross-peak between the NH of the Knv residue (H 8.78, 3-NH) and the 
-proton of the Mpr residue (H 4.45, H-8) indicated the connection between the Mpr 
and the Knv residues. The connectivity between the Aox and the Knv residues was 
shown by an HMBC cross-peak between the NH of the Aox residue (H 9.09, 23-NH) 
and the C-1 carbonyl carbon (C 163.8) of the Knv residue. The NH of the Abu residue 
(H 7.70, NH-17) was correlated to the carbonyl carbon of the Aox residue (C 159.5, 
C-19) in the HMBC spectrum, demonstrating that nazumazole D was a cyclic 
pentapeptide encompassing an oxazole ring. 
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Figure 3-3. Key COSY, TOCSY, HMBC and NOESY correlations in nazumazole D 
(3-1). 
 
 The molecular formula of nazumazole E (3-2) was assigned as C26H37N7O9 on 
the basis of HRESIMS. Characteristic structural features of nazumazole D were 
conserved in 3-2 as inferred from the NMR data (Table S3-1). There were subtle 
changes: the n-propyl side chain of the Knv residue was replaced by an isobutyl group; 
a Ser residue was substituted for the Abu residue. The NMR signals for the 
N--formyl-Dpr, Aox, and Mpr residues were observed in 3-2. The presence of the 
carbonyl-inserted leucine (Kle, Figure 3-4) was confirmed by the LC-MS analysis of 
the acid hydrolysate of nazumazole E after reduction with NaBH4 (Figure S3-21). The 
sequence of the five residues was assigned by interpretation of the ROESY and HMBC 
data (Figure S3-2a). 
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Figure 3-4. The structure of a-ketoleucine (Kle). 
Nazumazole F (3-3) had the molecular formula of C25H35N7O9. Comparison 
of the NMR data of 3-3 (Table S3-2) with those of 3-1 showed that a single amino acid 
substitution, Abu residue to Ser residue, from nazumazole D occurred in 3-3. The 
presence of the Knv residue was confirmed by the LC-MS analysis of the acid 
hydrolysate of the NaBH4-reduced nazumazole F. The amino acid sequence of 3-3 was 
deduced from the ROESY and HMBC data (Figure S3-2b), which showed that the Abu 
residue in nazumazole D was substituted for a Ser residue in nazumazole F. 
 The absolute configurations of the -amino acid residues in 3-1–3-3 were 
determined by Marfey’s method.54 Ala, Ser, Abu, Dpr, and Mpr residues were liberated 
by standard acid hydrolysis (6N HCl, 110 °C, 3 h). The Knv and Kle residues were 
converted to Nva and Leu residues, respectively, by oxidation with H2O2 prior to acid 
hydrolysis. Authentic samples of the isomers of 4-methylproline were prepared as 
described in chapter 2. LC-MS analyses revealed the presence of L-Ala, D-Abu, L-Dpr, 
and L-Nva in 3-1, L-Ala, D-Ser, L-Dpr, and L-Leu in 3-2, and L-Ala, D-Ser, L-Dpr, and 
L-Nva in 3-3 (Figure S3-22–S3-27). In our previous study on the structure elucidation 
68 
 
of nazumazoles A–C, cis-4-methyl-L-proline and trans-4-methyl-L-proline were only 
barely separable as were cis-4-methyl-D-proline and trans-4-methyl-D-proline. We 
searched for a better separation condition and found that a Phenyl-Hexyl column was 
most suitable (Figure 3-5). We were able to unambiguously assign the absolute 
configurations of the Mpr residue in 3-1–3-3 as cis-4-methyl-L-proline (Figure S3-28). 
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Figure 3-5. LC-MS chart of the four FDAA-derivatives of 4-methylproline using (a) 
COSMOSIL MS-II, (b) COSMOSIL NAP, and (c) Phenyl-Hexyl as the stationary 
phase (cis-L: cis-4-methyl-L-proline, trans-L: trans-4-methyl-L-proline, cis-D: 
cis-4-methyl-D-proline, trans-D: trans-4-methyl-D-proline); x-axis is retention time. 
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 Nazumazoles D–F (3-1–3-3) did not show cytotoxicity against P388 murine 
leukemia cells at a concentration of 50 M, but a mixture of nazumazoles A–C was 
cytotoxic. As previously mentioned, cyclotheonamide A from T. swinhoei Y is a potent 
inhibitor of trypsin and thrombin which cleave the carboxyl side of the amide bonds of 
basic amino acid residues such as Arg.
27
 The side chain of the ketoarginine (Kar) 
residue of cyclotheonamide A binds to the specificity pocket of either trypsin or 
thrombin and the active site hydroxy group of the Ser residue in the enzyme forms a 
covalent bond with the ketone carboxyl carbon of the Kar residue.
29
 Against this 
background we reasoned that nazumazoles might inhibit proteases that cleave the 
amide bond adjacent to a hydrophobic amino acid residue. We found that nazumazoles 
D, E, and F inhibited chymotrypsin with IC50 values of 2 M, 3 M, and 10 M, 
respectively (Figure S3-29) and they did not inhibit trypsin or thrombin at a 
concentration of 50 M.56 
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3.3. Experimental Section 
 
General Experimental Procedures.  
Optical rotations were measured on a Jasco DIP-1000 polarimeter. UV spectra 
were measured on a Shimadzu BioSpec-1600 spectrophotometer. NMR spectra were 
measured on a JEOL alpha 600 NMR spectrometer and referenced to the solvent peak: 
H 2.49 and C 39.5 for DMSO-d6. ESI mass spectra were recorded on a JEOL 
JMS-T100LC mass spectrometer. LC-MS experiments were performed on a Shimadzu 
LC-20AD solvent delivery system and interfaced to a Bruker amaZon SL mass 
spectrometer. The results of XTT assay and enzyme inhibition assay were recorded 
with a Molecular Devices SPECTRA max M2. 
 
Extraction and Isolation. 
The marine sponge Theonella swinhoei was collected at Hachijo Island 
(September 15, 1998) and kept frozen at -20 °C until processed. The sponge (22 kg, 
wet weight) was extracted with MeOH and n-PrOH-H2O (3:1). The MeOH extract was 
partitioned between H2O and Et2O. The organic layer was further partitioned between 
MeOH-H2O (9:1) and n-hexane. The aqueous n-PrOH extract was partitioned between 
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n-PrOH-H2O-MeOH (3:2:1) and n-hexane. The H2O and aqueous MeOH layers from 
the MeOH extract and the aqueous alcoholic layer of the n-PrOH-H2O (3:1) extract 
were combined and subjected to ODS column chromatography by elution with H2O, 
MeOH-H2O (1:1), and CHCl3-MeOH (1:1). The CHCl3-MeOH (1:1) fraction was 
subjected to ODS column chromatography with a step-wise elution with n-PrOH-H2O 
(2:3) and n-PrOH-H2O (3:1). The former fraction was subjected to gel permeation 
chromatography (Sephadex LH-20) with CHCl3-MeOH (1:1). The fraction eluting 
after cyclotheonamide A
27
 afforded a brownish oil (5 g). A 550 mg portion of this 
material was subjected to ODS column chromatography with a step-wise elution with 
MeCN-H2O (1:9), MeCN-H2O (1:3) and MeCN-H2O (2:3). The first two fractions 
were combined and subjected to gel permeation HPLC on TSK gel -2500, eluting 
with MeCN-H2O (3:7) containing 0.2% acetic acid to afford twelve fractions (A–L). 
Fractions E–I were combined and subjected to gel permeation HPLC on Shodex 
GS320-20FS, eluting with MeOH containing 0.25% acetic acid to afford three 
fractions (M–O). Fractions N and O were separated by recycle-HPLC on Shodex 
GS320-20FS, eluting with MeOH containing 0.25% acetic acid to afford four fractions 
(P–S). Fractions P and R, and Q and S were combined, respectively (fractions T and U). 
Fractions M, T and U were purified by ODS-HPLC on COSMOSIL 5C18-AR-II with 
73 
 
gradient elution from MeCN-H2O (1:9) to MeCN-H2O (1:4) containing 0.5% acetic 
acid. Finally, each fraction was purified by gel permeation HPLC on Shodex 
GS320-HQ with gradient elution from MeCN-H2O (1:9) to MeCN-H2O (3:7) 
containing 0.5% acetic acid to afford nazumazole D (3-1, 1.8 mg), E (3-2, 1.0 mg) and 
F (3-3, 0.7 mg). 
 
Nazumazole D (3-1): yellow powder; []D -9 (c 0.1, MeOH); UV (MeOH)max (log ) 
220.0 (3.7); 
1
H and 
13
C NMR (DMSO-d6), Table 3-1; HRESIMS m/z 598.2580 [M + 
Na]
+
 (calcd for C26H37N7NaO8, 598.2601,  -2.1 mmu). 
Nazumazole E (3-2): yellow powder; []D -17 (c 0.1, MeOH); UV (MeOH)max (log ) 
220.5 (3.7); 
1
H and 
13
C NMR (DMSO-d6), Table S3-1; HRESIMS m/z 614.2529 [M + 
Na]
+
 (C26H37N7NaO9, 614.2550,  -2.1 mmu). 
Nazumazole F (3-3): yellow powder; []D -46 (c 0.05, MeOH); UV (MeOH) max (log 
 217.5 (3.4); 1H and 13C NMR (DMSO-d6), Table S3-2; HRESIMS m/z 600.2408 [M 
+ Na]
+
 (calcd for C25H35N7NaO9, 600.2394,  +1.4 mmu). 
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Marfey’s Analyses of Nazumazoles D–F (3-1–3-3).  
To a solution of 3-1 (50 g) in MeOH (1.0 mL) was added NaBH4 (1.0 mg) 
and left at rt for 10 min. 5% Acetic acid in H2O (1.0 mL) was added to the mixture and 
the solution was applied to an ODS column and eluted with H2O and MeCN-H2O (3:2). 
The aqueous MeCN fraction was dried in vacuo to afford a diastereomeric mixture of 
dihydronazumazole D. In the same manner, dihydronazumazoles E and F were 
prepared. Reduced peptides were hydrolyzed in 6 N HCl at 110 °C for 3 h. The 
reaction mixtures were dried by a stream of N2 and redissolved in H2O (100 L). 1% 
L-FDAA solution in acetone (100 L) and 1 M NaHCO3 in H2O (20 L) were added to 
the solution, and kept at 55 °C for 30 min. After neutralization with 2 N HCl (10 L), 
the reaction mixtures were analyzed by LC-MS on COSMOSIL 2.5C18-MS-II with 
gradient elution from MeCN-H2O (1:9) to MeCN-H2O (7:3) containing 0.5% acetic 
acid for 32 min. Standard amino acids were derivatized with L-FDAA and analyzed by 
LC-MS in the same manner. Retention times of amino acids and LC-MS charts are 
shown in Table S3-3 and Figures S3-22–S3-25. 
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LC-MS Analyses of the Four FDAA-derivatives of 4-methylproline. 
The synthetic procedures of cis-4-methyl-L-proline and trans-4-methyl- 
L-proline were described in the previous chapter. Solutions of cis-4-methyl-L-proline 
(0.7 mg) and trans-4-methyl-L-proline (0.9 mg) in H2O (100 L) were derivatized with 
D-/L-FDAA in the same manner as Marfey’s analyses of nazumazoles D–F, 
respectively. cis-/trans-4-Methyl-L-proline derivatized with D-FDAA were used as the 
standards of enantiomers of cis-/trans-4-methyl-D-proline. The four FDAA-derivatized 
4-methylproline were analyzed by LC-MS on COSMOSIL 2.5C18-MS-II, COSMOSIL 
2.5 NAP, or phenomenex Phenyl-Hexyl with gradient elution from 10% to 50% 
aqueous MeCN containing 0.5% acetic acid for 57 min (Figure S3-28). 
 
Oxidation of Knv and Kle Residues.   
To the solutions of 3-1, 3-2, and 3-3 (100 g, each) in 5% NaOH in H2O (200 
L) was added 30% H2O2 (50 L) and the mixture was kept at 65 °C for 20 min. The 
reaction products were dried and subjected to acid hydrolysis, derivatization, and 
LC-MS analysis as described above (Table S3-3, and Figure S3-26 and S3-27). 
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Enzyme Inhibition Assay.  
Enzyme inhibitory assays were performed in triplicate in 96-well micro plates. 
Bovine -chymotrypsin (25 ng; Sigma-Aldrich C4129) in a buffer (70 L of a 20 mM 
Tris-HCl solution, pH 7.8) was preincubated for 15 min at 37 °C in the presence of 1 
L of a sample solution or DMSO as negative control. After preincubation, 
chymotrypsin substrate {Suc-Leu-Leu-Val-Tyr 4-methylcoumaryl-7-amide (MCA), 5 
L of 2 mM solution in DMSO) was added, and the solution was incubated for 1 h at 
37 °C. The reaction was stopped by adding a solution of sodium acetate (80 L, 1 M, 
pH 4.0). Formation of MCA was measured by fluorometry (the excitation and emission 
wavelengths were 355 and 460 nm, respectively). 4-(2-Aminoethyl) benzenesulfonyl 
fluoride hydrochloride (AEBSF; 1 L of a 4 mM solution in H2O) was used as a 
positive control. Trypsin and thrombin inhibition assays were performed in the same 
manner using either bovine trypsin (1 g/L solution; Wako 208-13954) or bovine 
thrombin (0.5 g/L solution; Sigma-Aldrich); trypsin substrate (Bz-L-Arg-pNA•HCl, 
5 mM solution prepared in DMSO) or thrombin substrate (Bz-Phe-Val-Arg-pNA•HCl, 
1.3 mM solution in H2O). Formation of pNA was measured by UV absorption (405 
nm). 
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3.4. Supporting Information 
Table S3-1.
 1
H (600 MHz) and 
13
C NMR Data (150 MHz) of Nazumazole E (3-2) in 
DMSO-d6. 
amino acid position C,
a, b type H,
a (J in Hz) ROESY HMBC 
L-Kle 1 164.1, C 
   
 
2 unassignedc 
   
 
3 53.1, CH 4.92, m 
  
 
4 37.8, CH2 1.71, m 
  
   
1.46, m 
  
 
5 24.6, CH 1.78, m 
  
 
6 23.2, CH3 0.92, d (6.4) 
  
 
5-Me 20.9, CH3 0.89, d (6.4) 
  
 
3-NH 
 
8.67, d (6.9) 8 7 
cis-4-methyl-L-proline 7 172.0, C 
   
 
8 59.4, CH 4.39, m 3-NH 13 
 
9 36.8, CH2 2.36, m 
  
   
1.19, m 
 
7 
 
10 33.2, CH 2.18, m 
  
 
11 53.8, CH2 3.87, dd (7.3, 9.2) 14 
 
   
2.90, t (10.5) 
  
 
12 15.9, CH3 0.95, d (6.0) 
  
N--CHO-L--Dpr 13 170.8, C 
   
 
14 50.5, CH 4.69, m 11a 
 
 
15 39.2, CH2 3.53, m 
  
 
14-NH 
 
8.08, d (6.9) COH COH 
 
15-NH 
 
7.43 dd, (6.0, 6.4) 17-NH 16 
 
COH 160.8, CH 7.97, s 
 
14 
D-Ser 16 170.9, C 
   
 
17 56.1, CH 4.38, m 
 
19 
 
18 61.8, CH2 3.58, m 
 
16 
   
3.53, m 
 
16 
 
17-NH 
 
7.82, d (9.2) 15-NH 19 
L-Aox 19 159.8, C 
   
 
20 135.0, C 
   
 
21 142.1, CH 8.60, s 
 
20, 22 
 
22 163.6, C 
   
 
23 43.5, CH 5.02, m 
 
22 
 
24 15.6, CH3 1.55, d (7.3) 
 
22 
23-NH 
 
9.12, d (8.2) 
 
1 
a
Recorded at 25 °C. 
b13
C chemical shifts were obtained by HSQC and HMBC experiments. 
c
No HMBC correlation to amide carbonyl carbon was observed. 
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Table S3-2. 
1
H (600 MHz) and 
13
C NMR Data (150 MHz) of Nazumazole F (3-3) in 
DMSO-d6. 
amino acid position C,
a, b type H,
a (J in Hz) ROESY HMBC 
L-Knv 1 164.3, C 
   
 
2 unassignedc 
   
 
3 54.3, CH 4.86, m 17-NH 
 
 
4 31.1, CH2 1.90, m 
  
   
1.53, m 
  
 
5 18.4, CH2 1.45, m 
  
   
1.38, m 
  
 
6 13.1, CH3 0.89, t (7.3) 
  
 
3-NH 
 
8.78, d (6.4) 8 
 
cis-4-methyl-L-proline 7 unassignedc 
   
 
8 59.2, CH 4.39, m 3-NH 
 
 
9 36.5, CH2 2.35, m 
  
   
1.18, m 
  
 
10 32.8, CH 2.17, m 
  
 
11 53.6, CH2 3.87, dd (7.3, 9.2) 14 
 
   
2.89, t (10.5) 
  
 
12 15.6, CH3 0.94, d (6.4) 
  
N--CHO-L--Dpr 13 unassignedc 
   
 
14 50.1, CH 4.69, m 11a, COH 
 
 
15 38.8, CH2 3.53, m 
  
 
14-NH 
 
8.07, d (6.9) COH COH 
 
15-NH 
 
7.46, t (6.0) 
 
16 
 
COH 160.5, CH 7.97, s 14 14 
D-Ser 16 170.9, C 
   
 
17 56.0, CH 4.38, m 
  
 
18 61.5, CH2 3.56, m 
  
   
3.53, m 
  
 
17-NH 
 
7.80, d (9.2) 3 19 
L-Aox 19 159.7, C 
   
 
20 135.0, C 
   
 
21 141.8, CH 8.60, s 12, 24 20, 22 
 
22 163.5, C 
   
 
23 43.0, CH 5.02, m 
 
22 
 
24 15.2, CH3 1.54, d (7.3) 
 
22 
23-NH 
 
9.20, d (8.2) 
 
1 
a
Recorded at 25 °C. 
b13
C chemical shifts were obtained by HSQC and HMBC experiments. 
c
No HMBC correlation to amide carbonyl carbon was observed. 
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Table S3-3. Results of Marfey’s Analyses of Nazumazoles D–F (3-1–3-3). 
 
retention time (min) 
amino 
acid 
L D sample 
Ser 7.2 7.9 7.9 (3-2, 3-3) 
Ala 9.8 11.8 9.7 (3-1–3-3) 
Abu 11.2 13.6 13.7 (3-1) 
Dpr 15.9 16.9 15.9 (3-1–3-3) 
Nva 13.5 15.9 13.3 (3-1), 13.5 (3-3) 
Leu 15.4 17.6 15.4 (3-2) 
 
 
Figure S3-1. Two-dimensional LC-MS chart of nazumazoles D–F (3-1–3-3) and 
nazumazoles A–C (2-1–2-3) in crude sample; x-axis is retention time and y-axis is m/z. 
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Figure S3-2. Key COSY, TOCSY, HMBC and ROESY correlations in (a) nazumazoles 
E and (b) F. 
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Figure S3-3. 
1
H NMR spectrum of nazumazole D (3-1) in DMSO-d6 (600 MHz). 
 
Figure S3-4. COSY spectrum of nazumazole D (3-1) in DMSO-d6 (600 MHz). 
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Figure S3-5. HSQC spectrum of nazumazole D (3-1) in DMSO-d6 (600 MHz). 
 
Figure S3-6. TOCSY spectrum of nazumazole D (3-1) in DMSO-d6 (600 MHz). 
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Figure S3-7. HMBC spectrum of nazumazole D (3-1) in DMSO-d6 (600 MHz). 
 
Figure S3-8. NOESY spectrum of nazumazole D (3-1) in DMSO-d6 (600 MHz). 
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Figure S3-9. 
1
H NMR spectrum of nazumazole E (3-2) in DMSO-d6 (600 MHz). 
 
Figure S3-10. COSY spectrum of nazumazole E (3-2) in DMSO-d6 (600 MHz). 
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Figure S3-11. HSQC spectrum of nazumazole E (3-2) in DMSO-d6 (600 MHz). 
 
Figure S3-12. TOCSY spectrum of nazumazole E (3-2) in DMSO-d6 (600 MHz). 
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Figure S3-13. HMBC spectrum of nazumazole E (3-2) in DMSO-d6 (600 MHz). 
 
Figure S3-14. ROESY spectrum of nazumazole E (3-2) in DMSO-d6 (600 MHz). 
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Figure S3-15. 
1
H NMR spectrum of nazumazole F (3-3) in DMSO-d6 (600 MHz). 
 
Figure S3-16. COSY spectrum of nazumazole F (3-3) in DMSO-d6 (600 MHz). 
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Figure S3-17. HSQC spectrum of nazumazole F (3-3) in DMSO-d6 (600 MHz). 
 
Figure S3-18. TOCSY spectrum of nazumazole F (3-3) in DMSO-d6 (600 MHz). 
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Figure S3-19. HMBC spectrum of nazumazole F (3-3) in DMSO-d6 (600 MHz). 
 
Figure S3-20. ROESY spectrum of nazumazole F (3-3) in DMSO-d6 (600 MHz). 
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Figure S3-21. LC-MS charts of the DAA-derivatives of reduced Knv (m/z 400) and 
Kle (m/z 414).  
 
 
Figure S3-22. LC-MS charts of Marfey’s analyses of nazumazoles D–F (3-1–3-3) 
(Ser). 
 
 
Figure S3-23. LC-MS charts of Marfey’s analyses of nazumazoles D–F (3-1–3-3) (Ala). 
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Figure S3-24. LC-MS charts of Marfey’s analyses of nazumazoles D–F (3-1–3-3) 
(Abu). 
 
 
Figure S3-25. LC-MS charts of Marfey’s analyses of nazumazoles D–F (3-1–3-3) (Dpr). 
 
 
Figure S3-26. LC-MS charts of Marfey’s analyses of nazumazoles D–F (3-1–3-3) (Nva). 
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Figure S3-27. LC-MS charts of Marfey’s analyses of nazumazoles D–F (1–3) (Leu). 
 
 
Figure S3-28. LC-MS charts of Marfey’s analyses of nazumazoles D–F (3-1–3-3) 
(Mpr). 
 
 
 
 
 
 
 
 
 
 
93 
 
  
 
Figure S3-29. The graphs of chymotrypsin inhibitory assay of nazumazoles D (a), E 
(b) and F (c).  
  
a b 
c 
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Chapter 4. 
Theonellamide H, a cytotoxic peptide with colony dependent distribution from the 
marine sponge Theonella swinhoei 
 
 
4.1. Introduction 
 
 In several reports describing the origins of natural products from marine 
invertebrates, differences of chemical contents among individual contents were reported, e. 
g., patellamides
57
 in the ascidian Lissoclinum patella
58
 and dysiherbaine
59
 in the sponge 
Lendenfeldia chondrodes.
60
 The presence of these compounds was attributed to the 
presence of the biosynthetic genes of these compounds in the producing cyanobacteria. 
Considering these reports, we hypothesized that the metabolic profiles of marine 
invertebrates are different from colony to colony owing to the diversity of bacterial 
composition. In most previous research on the isolation of secondary metabolites, 
conspecifics collected at the same region were extracted together and no attention was 
payed to their individual differences. To utilize bacterial resources in marine invertebrates 
more efficiently, we compared metabolic profiles by individual sponge colonies and 
searched for the compound which was contained in only selected colonies. 
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4.2. Result and Discussion 
 
 We collected colonies of the marine sponge Theonella swinhoei with yellow 
interior (T. swinhoei Y) at Hachijo Island, Tokyo, Japan. We selected 15 colonies 
(YT-1–YT-15) and extracted them separately. First, we examined the homogeneity of 
chemical profile within one specimen. To test this, we obtained two pieces (YT-11-1 
and YT-11-2) from different parts of a large colony (YT-11), extracted them with 
MeOH, and analyzed their chemical profiles by LC-MS. The compositions of 
secondary metabolites were compared by analyzing the total ion chromatograms. 
YT-11-1 and YT-11-2 exhibited an identical chemical profile (Figure S4-3). Then, a 
10–20 g piece was taken from each colony, extracted, and the extract was analyzed by 
LC-MS (Figure S4-1–S4-4). The contents of the major compounds, such as onnamide 
A (and its analogues)
22
, aurantoside A and B
26
, and nazumamide A
61
, were conserved 
among all colonies. However, we found that the quantity of several metabolites was 
variable among colonies. Notably, 7 out of 15 colonies contained the compound with 
molecular ions at m/z 1703 and 1705. Therefore, we intended to isolate this compound, 
and conduct structure determination and evaluation of biological activity. 
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 The colony (YT-11) which contained the compound was extracted with EtOH 
and partitioned between H2O and CHCl3. The BuOH extract of the aqueous layer was 
sequentially subjected to ODS column chromatography and two rounds of RP-HPLC 
to obtain theonellamide H (4-1, 1.2 mg).
62
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 The molecular formula of 4-1 was determined by HRESIMS as 
C74H95BrN16O26, which was smaller than that of theonegramide (4-2)
63
 by one 
methylene unit. Theonegramide has been isolated from T. swinhoei collected at the 
Philippines, and this compound is a congener of theonellamide D.
64a
 The peptide 
nature of 4-1 was indicated by the NH signals between δH 7.43 and 8.67 in the 
1
H 
NMR spectrum. In addition, an anomeric carbon signal (δC 88.2, δH 4.98) was 
observed in the HSQC spectrum of 4-1, suggesting the presence of a sugar portion. 
Interpretation of the COSY, HSQC, TOCSY, HMBC, and NOESY spectra in 
DMSO-d6/H2O (4:1) at 50 °C revealed the presence of one residue each of 
3-amino-4-hydroxy- 6-methyl-8-phenyl- 5,7-octadienoic acid (Apoa), Phe, Ser (Ser-2), 
Thr, histidinoalanine, α-aminoadipic acid (Aad), isoserine (Iser), 
p-bromophenylalanine (BrPhe), β-hydroxyasparagine (OHAsn), and Asn in 4-1. In 
order to observe signals buried under the huge water signal, NMR spectra were also 
measured at 30 °C. By this experiment, the signals of one additive Ser residue (Ser-1) 
appeared (see Table 4-1).  
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Table 4-1. 
1
H and 
13
C NMR data (600 MHz) of theonellamide H (4-1) in DMSO-d6/H2O (4:1). 
amino acid position C,
a, b, c type H,
a (J in Hz)  amino acid position C,
a, b, c type H,
a (J in Hz) 
Ser-1d  56.4, CH 3.72, m  Arabinose 1 88.2, CH 4.98, d (8.8) 
  60.8, CH2 3.63, m   2   69.1, CH 3.67, m 
 NH  7.92, m   3 72.6, CH 3.43, m 
Apoa  36.9, CH2 2.38, m   4,5
e unassigned unassigned 
   2.11, dd (12.6, 3.3)  Aad  54.2, CH 3.93, m 
  52.4, CH 4.10, m    31.7, CH2 1.77, m 
  67.9, CH 4.25, dd (8.8, 3.9)     1.53, m 
  132.4, CH 5.20, d (8.8)    21.9, CH2 1.40, m 
  135.7, C     35.4, CH2 2.23, m 
 -Me 12.8, CH3 1.66, s     1.98, m 
  133.3, CH 6.63, d (16.5)   NH  7.63, m 
  127.7, CH 6.50, d (16.5)  Iser  69.7, CH 4.11, m 
  137.6, C     43.0, CH2 3.90, m 
 2, 6 126.2, CH 7.40, d (7.7)     2.95, m 
 3, 5 128.9, CH 7.30, dd (7.7, 7.7)   NH  7.45, m 
 4 127.7, CH 7.19, m  BrPhe  55.0, CH 4.31, ddd (8.1, 8.1, 4.0) 
 NH  7.79, m    36.6, CH2 3.03, m 
Phe  54.2, CH 4.55, ddd (8.8, 8.0, 8.0)     2.66, m 
  38.6, CH2 2.82, dd (13.4, 8.0)   1’’’ 137.6, C  
   2.65, m   2’’’, 6’’’ 131.2, CH 7.04, d (8.3) 
 1’ 137.0, C    3’’’, 5’’’ 131.2, CH 7.27, d (8.3) 
 2’, 6’ 129.2, CH 7.16, m   6’’’ 120.0, CH  
 3’, 5’ 128.3, CH 7.22, m   NH  8.67, m 
 4’ 126.8, CH 7.17, m  OHAsn  54.2, CH 5.30, dd (8.3, 8.3) 
 NH  8.02, d (8.8)    72.0, CH 4.03, d (7.2) 
Ser-2  56.2, CH 4.48, m   NH2  7.23, m 
  61.5, CH2 3.66, m     6.77, brs 
   3.59, m   NH  8.33, m 
 NH  8.66, m  Asn a 51.5, CH 4.47, m 
Thr  58.0, CH 4.22, m   b 36.6, CH2 2.56, m 
  68.2, CH 3.56, m     2.24, m 
  21.0, CH3 0.90, d (6.1)   NH2  unassigned 
sHis  53.9, CH 4.82, m   NH  7.78, m 
  26.0, CH2 3.23, m  sAla  50.6, CH 5.05, m 
   2.99, m    49.8, CH2 4.89, d (13.7) 
 2’’ 136.5, CH 8.90, s     4.20, m 
 4’’ 131.4, C    NH  8.22, d (9.3) 
 5’’ 123.6, CH 7.24, s  
NH  8.35, m      
a 
Recorded at 50 °C. 
b13
C chemical shifts were obtained by HSQC and HMBC experiments.  
c13
C chemical shifts of amide carbonyl carbons were not assigned.  
d1
H and 
13
C chemical shifts of Ser-1 residues were obtained from NMR spectra at 30 °C.  
e
Overlapped by the signal of water. 
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The amino acid sequence of 4-1 was determined by NOESY spectrum 
measured at 30 °C and 50 °C (Figure 4-1). The NOESY correlations between the amide 
proton and the -proton were observed between residues: Ser-1 (H 7.92) and Apoa (H 
2.37 and H 2.09) at 30 °C; Apoa (H 7.90) and Phe (H 4.54) at 30 °C; Phe (H 8.02) 
and Ser-2 (H 4.48) at 50 °C; Ser-2 (H 8.76) and Thr (H 4.23) at 30 °C; Thr (H 7.43) 
and sHis (H 4.82) at 50 °C; Iser (H 7.52) and BrPhe (H 4.27) at 30 °C; BrPhe (H 
8.72) and OHAsn (H 5.29) at 30 °C; OHAsn (H 8.44) and Asn (H 4.45) at 30 °C; Asn 
(H 7.78) and sAla (H 5.05) at 50 °C; sAla (H 8.27) and Ser-1 (H 3.72) at 30 °C. In 
addition, NOESY correlations between the signal of amide NH proton of sHis residue 
(H 8.46) and the signal of -protons of Aad residue (H 2.23 and H 1.99) at 30 °C were 
observed, which indicated the amide bond between -carbonyl carbon of Aad residue 
and sHis residue. No NOESY signal was observed from the signal of NH proton of Aad 
residue. However, taking the molecular formula and the number of unsaturation into 
account, compound 4-1 should construct macrocyclic structure. Therefore, Iser and Aad 
should form the last amide bond
65
, and the amino acid sequence of 4-1 was determined 
as almost identical to that of 4-2. β-Methyl-p-bromophenylalanine residue in 4-2 was 
substituted for BrPhe in 4-1. HMBC cross-peaks between the anomeric proton signal 
(δH 4.98) and carbon signals in the imidazole ring (δC 131.4 and δC 136.5) indicated that 
100 
 
the sugar portion was attached at C-1 to the remaining nitrogen on the imidazole ring of 
histidinoalanine residue. 
 
Figure 4-1. Key NOESY correlations in 4-1. 
 
 The (5E, 7E) geometry of the Apoa moiety was elucidated from the 
13
C NMR 
chemical shift of the ε-methyl signal at δc 12.8 and the proton coupling constant 
(
3
JH-/H- = 16.5 Hz) associated with the trans-disubstituted olefin. The absolute 
configuration of each amino acid residue in 4-1 was determined by Marfey’s method.54 
Phe, Ser, Thr, histidinoalanine, Aad, Iser, and BrPhe were liberated by standard acid 
hydrolysis. OHAsn and Asn were obtained as β-hydroxyasparatic acid (OHAsp) and 
Asp, respectively. With hydrogenation before acid hydrolysis, Apoa was obtained as 
3-amino-4-hydroxy-6-methyl-8-phenyl-octanoic acid (H4-Apoa). Standards of 
histidinoalanine, BrPhe, OHAsp, and H4-Apoa were obtained from the hydrolysate of 
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the mixture of theonellamide A, D, and E (4-3–4-5).64a Marfey’s analysis with detection 
by ESI-MS revealed the presence of L-Phe, L-Ser, L-allo-Thr, L-histidino-D-alanine, 
L-Aad, L-Iser, L-BrPhe, (2S, 3R)-OHAsn, L-Asn, and (3S, 4S)-Apoa (Figure S4-17–
S4-25).
66
 Although the absolute configuration of Iser residue in 4-2 was assigned as R, 
L-Iser was detected by Mafey’s analysis of 4-1. 
The 
1
H NMR data suggested that the sugar portion was arabinose. To identify 
the sugar, acid hydrolysate of 4-1 was subjected to 3-phenylthiocarbamoylthiazoline- 
4(R)-carboxylate derivatization.
67,68
 The derivative was analyzed by LC-MS and its 
retention time was compared with those of authentic samples of both D- and L-arabinose 
(Figure S4-16). From this result, the sugar portion was established as L-arabinose. 
 Theonellamide H exhibited moderate cytotoxicity against HeLa cells with an 
IC50 value of 1.9 M (Figure S4-26). This cytotoxicity was almost same as that of 
theonellamides A–E against P388 murine leukemia cells.64a 
 As described above, there are several morphologically distinct types in the 
marine sponge T. swinhoei, and they have different chemical profiles. 
Theonellamides
20,64
 and their analogues, theonegramide
63
 and theopalauamide
37
, had 
been isolated from T. swinhoei W. To the best of our knowledge, theonellamide H is the 
first analogue of theonellamides which was isolated from T. swinhoei Y. 
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4.3. Experimental Section 
 
General Experimental Procedures. 
Optical rotations were measured on a Jasco DIP-1000 polarimeter. UV spectra 
were measured on a Shimadzu BioSpec-1600 spectrophotometer. NMR spectra were 
measured on a JEOL alpha 600 NMR spectrometer and referenced to the solvent peak: 
H 2.49 and C 39.5 for DMSO-d6. ESI mass spectra were recorded on a JEOL 
JMS-T100LC mass spectrometer. LC-MS experiments were performed on a Shimadzu 
LC-20AD solvent delivery system and interfaced to a Bruker amaZon SL mass 
spectrometer. The result of XTT assay was recorded with a Molecular Devices 
SPECTRA max M2. 
 
Comparing the Chemical Profiles in T. swinhoei Y by Colonies. 
The marine sponges T. swinhoei with yellow interior (T. swinhoei Y) were 
collected at Hachijo Island and kept frozen at -20 °C until processed. The small amounts 
(10–20 g) taken from 15 sponge colonies (YT-1–YT-15) were extracted with MeOH and 
the extracts were dried in vacuo. The extracts were separately applied to a column of 
ODS ( 5 mm × 10 mm) and eluted with MeOH. The MeOH eluates were analyzed by 
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LC-MS on COSMOSIL 2.5C18-MS-II with gradient elution from H2O to MeCN 
containing 0.5% acetic acid for 70 minutes. 
 
Extraction and Isolation. 
The sponge YT-11 (850 g, wet weight) was extracted with EtOH. The extract 
was partitioned between H2O and CHCl3. The water layer was extracted with BuOH. 
The BuOH layer was subjected to ODS column chromatography with a stepwise elution 
with MeCN-H2O (1:4), MeCN-H2O (3:7), MeCN-H2O (2:3), and MeCN-H2O (1:1). The 
fraction eluted with MeCN-H2O (2:3) was subjected to ODS-HPLC on COSMOSIL 
5C18-MS-II. Gradient elution was performed using solvent A (50 mM KH2PO4 aqueous 
solution) and solvent B (n-PrOH); from A:B (4:1) to A:B (1:1). The fraction that 
contained the compound exhibiting ions at m/z 1703 and 1705 in ESIMS was further 
purified by ODS-HPLC on COSMOSIL 5C18-AR-II with gradient elution from 
MeCN-H2O (3:7) to MeCN-H2O (1:1) containing 0.5% acetic acid to afford 
theonellamide H (1.2 mg). 
To increase the amount of theonellamide H, we isolated the compound from the 
extract of T. swinhoei Y made in 1999. The marine sponge T. swinhoei Y was collected 
at Hachijo Island (22 kg, wet weight) was extracted with MeOH and n-PrOH-H2O (3:1). 
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The MeOH extract was partitioned between H2O and Et2O. The organic layer was 
further partitioned between MeOH-H2O (9:1) and n-hexane. The aqueous n-PrOH 
extract was partitioned between n-PrOH-H2O-MeOH (3:2:1) and n-hexane. The H2O 
and aqueous MeOH layers from the MeOH extract and the aqueous alcoholic layer of 
the n-PrOH-H2O (3:1) extract were combined and subjected to ODS column 
chromatography by elution with H2O, MeOH-H2O (1:1), and CHCl3-MeOH (1:1). The 
CHCl3-MeOH (1:1) fraction was subjected to ODS column chromatography with a 
step-wise elution with H2O, n-PrOH-H2O (2:3), and n-PrOH-H2O (3:1). The fraction 
eluted with H2O was extracted with BuOH. The BuOH extract (24 g) was dissolved in 
CHCl3-MeOH (1:1) and kept in freezer. 1 g portion of this material was subjected to 
ODS column chromatography with a stepwise elution with MeCN-H2O (1:3), 
MeCN-H2O (9:11), and MeCN-H2O (3:2). The fraction eluted with MeCN-H2O (9:11) 
was subjected to ODS-HPLC on COSMOSIL 5C18-AR-II with gradient elution from 
MeCN-H2O (3:7) to MeCN containing 0.5% acetic acid. The compound was further 
purified by RP-HPLC on COSMOSIL -Nap with gradient elution from MeCN-H2O 
(1:3) to MeCN-H2O (1:1) containing 0.5% acetic acid to afford theonellamide H (2.2 
mg). 
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Theonellamide H (4-1): pale yellow powder; []D -19 [c 0.05, n-PrOH-H2O (2:1)]; UV 
[n-PrOH-H2O (2:1)] max (log ) 210.5 (4.62) 278.0 (4.20); 
1
H and 
13
C NMR 
{DMSO-d6/H2O (4:1)}, Table 4-1 and Table S4-1; HRESIMS m/z 1725.5701 (calcd for 
C74H95
79
BrN16O26, 1725.5685,  +1.7 mmu) 
 
Marfey’s Analysis of Theonellamide H (4-1). 
Compound 4-1 (100 g) was dissolved in 6N HCl (200 L) and heated at 
110 °C for 3 h. The mixture of theonellamides A, D, and E was hydrolyzed in the same 
manner. The solvent was evaporated with a stream of N2 gas, and then redissolved in 0.6 
M NaHCO3 (100 L). To the solution was added 3% FDNP-L-Val in EtOH (80 L) and 
the mixture was kept at 55 °C for 1 h. After neutralization with 3 N HCl (20 L), the 
reaction mixture was analyzed by LC-MS on COSMOCORE 2.6PBr with gradient 
elution from MeCN-H2O (1:9) to MeCN-H2O (7:3) containing 0.5% acetic acid for 32 
min. Standard amino acids were derivatized with FDNP-D/L-Val, and then analyzed by 
LC-MS in the same manner. Standard amino acids of L-BrPhe and (2S, 3R)--OHAsp 
were obtained from the hydrolysate of the mixture of theonellamides A, D, and E. 
Retention times of amino acids and LC-MS charts are shown in Table S4-2 and S4-3,  
and Figure S4-17–S4-23. 
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Determination of the Absolute Configuration of Histidinoalanine Residue. 
The mixture of theonellamide A, D, and E (500 g) was dissolved in 6 N HCl 
(250 L) and subjected to acid hydrolysis for relatively long time (110 °C, 16 h). A half 
portion of the hydrolysate was derivatized with FDNP-L-Val and then analyzed by 
LC-MS in the same manner as Marfey’s analysis of 4-1. In additon to 
L-histidino-D-alanine, L-histidino-L-alanine was detected. The ratio of LD-isomer and 
LL-isomer was 3:1. Another half portion of the hydrolysate was derivatized with 
FDNP-D-Val, which was used as the standards of enantiomers of D-histidino-L-alanine 
and D-histidino-D-alanine. Retention times and LC-MS charts are shown in Table S4-4 
and Figure S4-24. 
 
Determination of the Absolute Configuration of 3-Amino-4-Hydroxy-6 
-Methyl-8-phenyl-5,7-octadienoic acid (Apoa) Residue. 
To a solution of compound 4-1 (100 g) in MeCN-H2O (1:1, 1 mL) was added 
10% Pd/C (2 mg), and the mixture was stirred under the atmosphere of H2 for 18 h. The 
mixture was filtered on Celite and the solvent was dried in vacuo to afford a 
diastereomitic mixture of tetrahydrotheonellamide H. The reduced peptide was 
subjected to acid hydrolysis, derivatization with FDNP-L-Val, and LC-MS analysis as 
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described above. The standard amino acid of a diastereomitic mixture of 
3-amino-6-methyl-8-phenyl-octanoic acid (H4-Apoa) was obtained from the hydrolysate 
of the reduced mixture of Theonellamide A, D, and E and derivatized with FDNP- 
D/L-Val, and then analyzed by LC-MS in the same manner (Table S4-5 and Figure S4-25). 
 
Identification, and Determination of the Absolute Configuration of the Sugar 
portion in Theonellamide H (4-1). 
Compound 4-1 (60 g) was dissolved in 6 N HCl (200 L) and heated at 
110 °C for 3 h. The solvent was evaporated with a stream of N2 gas, and then dissolved 
in 10% HCl in MeOH (200 L). The reaction mixture was heated at 100 °C for 1h. 
After evaporation of the solvent, to the hydrolysate of 1 was added a solution of 
L-cysteine methyl ester hydrochloride in pyridine (2 mg/mL; 100 L) and then heated at 
60 °C for 1 h. Then, 5 L of phenylisothiocyanate was added and the solution was 
heated for a further hour at 60 °C. The solvent was evaporated, and the product was 
dissolved in MeOH (100 L). The reaction product was analyzed by LC-MS on 
COSMOSIL 2.5C18-MS-II with gradient elution from MeCN-H2O (1:9) to MeCN-H2O 
(3:17) containing 0.5% acetic acid for 60 minutes. L- and D-Arabinose were treated in 
the same manner. The retention times are shown in Table S4-2. The LC-MS chart is 
shown in Figure S4-16. 
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XTT Assay against HeLa Cells. 
HeLa human cervical cancer cells were cultured in Dulbecco’s modified 
Eagle’s medium (Wako Chemical) medium, supplemented with 100 U/mL of penicillin 
G (Wako Chemical), 100 mg/mL of streptomycin sulfate (Wako Chemical), and 10% 
fetal bovine serum (Gibco), at 37 °C under a 5% CO2 atmosphere. To each well of a 
96-well microplate containing 200 μL of tumor cell suspension (1 × 104 cells/mL) was 
added a sample after 24 h preincubation, and the plate was incubated for 72 h. After the 
addition of 50 µL of 3’-[1-(phenylaminocarbonyl)-3,4-tetrazolium]- 
bis(4-methoxy-6-nitro)benzenesulfonic acid hydrate (XTT) solution (1 mg/mL) 
containing 4% of phenazine methosulfate (PMS) solution (0.153 mg/mL) to each well, 
the plates were further incubated for 4 h. The absorbance at 450 nm was measured with 
a microplate reader. 
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2.4. Supporting Information 
Table S4-1. 
1
H and 
13
C NMR data (600 MHz) of theonellamide H (4-1) in DMSO-d6/H2O (4:1) at 30 °C. 
amino acid position C,
a, b, c type H,
a (J in Hz)  amino acid position C,
a, b, c type H,
a (J in Hz) 
Ser-1  56.4, CH 3.72, m  Arabinose 1 88.7, CH 4.97, d (7.7) 
  60.8, CH2 3.63, m   2  69.4, CH 3.64, m 
 NH  7.92, m   3 72.7, CH 3.39, m 
Apoa  37.2, CH2 2.37, m   4,5
d unassigned unassigned 
   2.09, m  Aad d unaasigned unassigned 
  unassigned
d 4.08, m    32.5, CH2 1.76, m 
  unassigned
d 4.25, m     1.52, m 
  132.8, CH 5.17, d (8.3)    22.6, CH2 1.39, m 
  unassigned
e     35.5, CH2 2.23, m 
 -Me 13.5, CH3 1.65, s     1.99, m 
  133.5, CH 6.63, (15.9)   NH  7.64, m 
  128.2, CH 6.50, d (15.9)  Iser e unassigned unassgined 
  unassigned
e     43.5, CH2 unassigned
d 
 2, 6 126.5, CH 7.41, d (7.7)     2.93, m 
 3, 5 128.9, CH 7.31, dd (7.7, 7.7)   NH  7.52, brd (6.6) 
 4 127.9, CH 7.19, m  BrPhe  55.4, CH 4.27, m 
 NH  7.90, m    36.8, CH2 3.02, m 
Phe  54.4, CH 4.54, m     2.64, m 
  39.0, CH2 2.81, m   1’’’ unassigned
e  
   2.63, m   2’’’, 6’’’ 131.5, CH 7.05, d (8.3) 
 1’ unassignede    3’’’, 5’’’ 131.5, CH 7.27, d (8.3) 
 2’, 6’ 129.5, CH 7.16, m   6’’’ unassginede  
 3’, 5’ 128.9, CH 7.23, m   NH  8.72, brs 
 4’ 127.2, CH 7.18, m  OHAsn  54.4, CH 5.29, m 
 NH  8.06, d (8.8)   d unassigned unassigned 
Ser-2  56.4, CH 4.49, m   NH2  7.23, m 
  61.8, CH2 3.66, m     6.87, brs 
   3.57, m   NH  8.44, m 
 NH  8.76, d (7.7)  Asn  51.8, CH 4.45, m 
Thr  unassigned
d 
4.23, m    36.8, CH2 2.54, m 
  68.7, CH 3.54, m     2.20, m 
  21.2, CH3 0.89, d (5.5)   NH2  unassigned 
sHis  54.1, CH 4.81, m   NH  7.83, m 
  26.2, CH2 3.22, m  sAla  50.8, CH 5.04, m 
   2.98, m    50.1, CH2 4.89, m 
 2’’ 136.8, CH 8.91, s     4.16, m 
 4’’ unassignede    NH  8.27, m 
 5’’ 123.9, CH 7.23, s  
NH  8.46, d (9.3)      
a 
Recorded at 50 °C. 
b13
C chemical shifts were obtained by HSQC experiments.  
c13
C chemical shifts of amide carbonyl carbons were not assigned.  
d
Overlapped by the signal of water. 
e
HMBC spectrum was not obatined at 30 °C, so these signals could not be assigned. 
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Figure S4-1. LC-MS charts of the extracts of YT-1–YT-4 (total ion chromatograms and MS chromatograms of the ion at m/z 1705). 
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Figure S4-2. LC-MS charts of the extracts of YT-5–YT-8 (total ion chromatograms and MS chromatograms of the ion at m/z 1705). 
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Figure S4-3. LC-MS charts of the extracts of YT-9–YT-11 (total ion chromatograms and MS chromatograms of the ion at m/z 1705). 
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Figure S4-4. LC-MS charts of the extracts of YT-12–YT-15 (total ion chromatograms and MS chromatograms of the ion at m/z 1705). 
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Figure S4-5. 
1
H NMR spectrum of theonellamide H (4-1) in DMSO-d6/H2O (4:1) (600 MHz, 50 °C). 
 
Figure S4-6. COSY spectrum of theonellamide H (4-1) in DMSO-d6/H2O (4:1) (600 MHz, 50 °C). 
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Figure S4-7. HSQC spectrum of theonellamide H (4-1) in DMSO-d6/H2O (4:1) (600 MHz, 50 °C). 
 
Figure S4-8. TOCSY spectrum of theonellamide H (4-1) in DMSO-d6/H2O (4:1) (600 MHz, 50 °C). 
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Figure S4-9. HMBC spectrum of theonellamide H (4-1) in DMSO-d6/H2O (4:1) (600 MHz, 50 °C). 
 
Figure S4-10. NOESY spectrum of theonellamide H (4-1) in DMSO-d6/H2O (4:1) (600 MHz, 50 °C). 
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Figure S4-11. 
1
H NMR spectrum of theonellamide H (4-1) in DMSO-d6/H2O (4:1) (600 MHz, 30 °C). 
 
Figure S4-12. COSY spectrum of theonellamide H (4-1) in DMSO-d6/H2O (4:1) (600 MHz, 30 °C). 
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Figure S4-13. HSQC spectrum of theonellamide H (4-1) in DMSO-d6/H2O (4:1) (600 MHz, 30 °C). 
 
Figure S4-14. TOCSY spectrum of theonellamide H (4-1) in DMSO-d6/H2O (4:1) (600 MHz, 30 °C). 
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Figure S4-15. NOESY spectrum of theonellamide H (4-1) in DMSO-d6/H2O (4:1) (600 MHz, 30 °C). 
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Table S4-2. Results of Marfey’s Analyses of Theonellamide H (4-1) and Analysis of the Absolute 
Configuration of the Arabinose Residue in 4-1. 
  retention time (min) 
amino acid L D Sample 
Aad 13.9 14.1 13.9 
Asp 12.7 13.0 12.7 
BrPhe 19.7 21.1 19.8 
Iser 13.3 13.1 13.3 
Phe 17.8 19.0 17.9 
Ser 12.4 12.8 12.5 
Thr 12.3 13.6 
12.8 
allo-Thr 12.8 13.3 
Arabinose 32.2 33.5 32.2 
 
Table S4-3. Result of Marfey’s Analysis of the OHAsp Residue in Theonellamide H (4-1). 
  retention time (min) 
amino acid (2S, 3R) (2R, 3S) Sample 
OHAsp 12.0 11.8 12.1 
 
Table S4-4. Result of Marfey’s Analysis of the HisAla Residue in Theonellamide H (4-1). 
  retention time (min) 
amino acid L, L L, D D, L D, D Sample 
HisAla 16.9 15.8 15.7 15.3 15.8 
 
Table S4-5. Result of Marfey’s Analysis of the H4-Apoa Residue in Theonellamide H (4-1). 
  retention time (min) 
amino acid (2S, 4R) (2R, 4S) Sample 
H4-Apoa 20.1, 20.8 22.6, 23.0 20.1, 20.9 
 
 
 
 
 
121 
 
 
Figure S4-16. LC-MS chart of the arabinose residue after converting into the methyl 
3-phenylthiocarbamoylthiazoline-4(R)-carboxylate derivative. 
 
 
Figure S4-17. LC-MS chart of Marfey’ s analysis of theonellamide H (4-1) (Phe). 
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Figure S4-18. LC-MS chart of Marfey’ s analysis of theonellamide H (4-1) (Ser, Iser). 
 
 
Figure S4-19. LC-MS chart of Marfey’ s analysis of theonellamide H (4-1) (Thr). 
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Figure S4-20. LC-MS chart of Marfey’ s analysis of theonellamide H (4-1) (Aad). 
 
 
Figure S4-21. LC-MS chart of Marfey’ s analysis of theonellamide H (4-1) (BrPhe). 
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Figure S4-22. LC-MS chart of Marfey’ s analysis of theonellamide H (4-1) (Asp). 
 
 
Figure S4-23. LC-MS chart of Marfey’ s analysis of theonellamide H (4-1) (OHAsp). 
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Figure S4-24. LC-MS chart of Marfey’ s analysis of theonellamide H (4-1) (HisAla). 
 
 
Figure S4-25. LC-MS chart of Marfey’ s analysis of theonellamide H (4-1) (H4-Apoa.). 
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Figure S4-26. The graph of XTT assay of 4-1 against HeLa cells; x-axis is concentration and y-axis 
is absorption at 450 nm. 
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Chapter 5. 
Conclusion 
 
 
 Traditionally, natural products have been important resource of drug 
discovery.
69
 As the success in penicillin brought natural products in market in 1940s, 
many research groups and pharmaceutical companies searched for new drugs from 
natural sources. From 1980s, along with the improvement of NMR and MS techniques, 
and other biological technologies, a variety of natural products with complex structure 
were isolated. From 1990s, pharmaceutical industries changed their attention to 
synthetic compounds as drug resource because high-through put screening (HTS) 
system was developed and the system enabled to test a lot of drug candidates in a short 
time. Until now, HTS and chemical library of synthetic compounds were the main 
research theme of companies, however, discovery rate of novel drugs is dropping 
dramatically.
70
 On the other hand, 40% approved drugs in U.S. were still natural 
products or their related compounds
71
, so natural products should be reexamined as 
drug resource.
72
 Actually, HTS hit rates of chemical library of natural products are 
better than those of synthetic compound chemical library.
73
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 In this research, we searched for new bioactive natural products from the 
sponge Theonella swinhoei. As a result, we found four cytotoxic compounds 
(nazumazoles A–C and theonellamide H) and three enzyme inhibitors (nazumazoles 
D–F). These compounds are difficult to detect by traditional UV- or bioassay-based 
separation. This result indicated that a large amount of chemical resources in sponges 
including T. swinhoei and their symbiotic bacteria are still underexplored. With 
progress in biological techniques, it is expected that new drugs and biological research 
tools will be discovered from sponges.  
 In 1986, the structure of a potent anti-tumor sponge metabolite, halichondrin 
B, was reported.
74
 The total synthesis of halichondrin B was achieved six years later
75
, 
and tested their synthetic analogues as anti-cancer agents in 2001.
76
 Finally, a synthetic 
analogue of halichondrin B, ER-086526, was approved as an anti-cancer drug in 2010. 
From this success story of halichondrin B, it is indicated that structure of bioactive 
natural products is necessary information to synthesize natural products and provide 
compounds for clinical trial or drug use. In addition, the structure of natural products is 
important to obtain biosynthetic genes of the compounds. 
 Moreover, structural information of bioactive compounds is essential for de 
novo synthesis of drug candidates. To design candidates, medicinal chemists must 
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consider an enormous number of chemical structures (theoretically, the number of 
organic molecules with molecular mass of less than 500 Da could be up to 10^60)
77
.
 
 
The structures of bioactive natural products and their modes of action can not only 
elucidate biological phenomenon at a molecular level
78
, but also provide the idea of 
drug candidates’ structure.79 
 In this research, with a number of degradation studies and analysis of 
derivatives, we determined the structures of seven compounds including the absolute 
configuration. While nazumazoles A–C (2-1–2-3), cyclic peptide dimers, exhibited 
cytotoxicity against leukemia cells, nazumazoles D–F (3-1–3-3), monomeric analogues 
of 2-1–2-3, showed no cytotoxicity against the same cell line. Recently, comparable 
phenomenon was observed in the study about cyclic hexapaptide dimers, 
antatollamides A and B.
80
 These results suggested that bioactivities of cyclic peptides 
could be changed or improved by dimerization through disulfide bonds. Theonellamide 
H was a structural analogue of theonellamide familiy. As described in chapter 1, the 
molecular target of theonellamide F was revealed as 3-hydroxysterols.21 By 
comparing the bioactivity against 3-hydroxysterols and cell membrane among 
theonellamide family, it can be revealed which structure is important for binding to 
sterols. 
130 
 
 Nazumazoles contain several unusual amino acids and D-amino acids, and 
have the structural similarity with peptides isolated from T. swinhoei, such as 
cyclotheonamide A
27
 and orbiculamide A.
50
 In addition, the absolute configurations of 
nazumazoles were conserved regardless of replacements of amino acids. These results 
indicated that nazumazoles should be non-ribosomal peptide. 4-methylproline is one of 
the most characteristic amino acids in nazumazoles. A few peptides isolated from T. 
swinhoei contain this amino acid (perthamides
81
 and mutremdamide A
82
), and this 
amino acid is mainly found in peptides isolated from cyanobacteria.
83
 While 
biosynthetic gene cluster of this amino acid was identified in cyanobacteria
84
, that has 
not been found in metagenome of T. swinhoei. If biosynthetic gene cluster of 
nazumazoles and 4-methylproline is established, it is expected not only to provide 
nazumazoles for biological research to reveal the mode of action, but also to find new 
class of active peptides in T. swinhoei by genome mining. 
 As mentioned in chapter 4, theonellamide H is the first analogue of 
theonellamides which was isolated from T. swinhoei Y. Both T. swinhoei Y and T. 
swinhoei W contain Ca. Entotheonella bacteria in their tissues, but their metabolic 
profiles are clearly different (chapter 1, figure 1-3).
41,42
 From the discovery of 
theonellamide H, it is supposed that the horizontal transmission of genes or bacteria 
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occurs among bacteria in sponges. We would like to compare metagenome or bacterial 
composition among colonies of T. swinhoei Y, and examine if there is a difference 
between the colony containing theonellamide H and the colony not containing the 
compound. 
 
 In summary, we found seven bioactive peptides from the sponge T. swinhoei Y 
and determined their structures. They have potential for being drug candidates or 
biological research tools. In addition, their information about structure and bioactivities 
will provide new insights into biochemistry and design of (semi)synthetic drug 
candidates. The result of this work is beneficial for development of chemistry, 
pharmacology, and biology. 
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